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Plants, herbs and ethnobotanicals have been used since ancient times and are still used 
throughout the world for health promotion and treatment of diseases, not only in human 
medicine but also in veterinary medicine. In recent years, the increasing interest in the 
use of herbal medicines involves critical issues, concerning the quality and safety of 
natural products in relation to their health claims. Consequently, the research to obtain 
scientific evidence on phytochemical characterization, molecular basis of biological 
activity and effectiveness of traditional remedies is increasingly needed. 
The main purpose of this research project was the evaluation of the biological activity of 
selected anti-inflammatory and anticancer phytoextracts in in vitro models based on cell 
cultures, in accordance with the European Directive 2010/63/EU on the protection of 
animals used for scientific purposes on the base of the “3Rs” principles.  
The first one was an inflammatory model based on primary culture of porcine aortic 
endothelial cells (pAECs) stimulated by LPS. This in vitro model was employed to 
evaluate the biological activity of different Boswellia serrata extracts and a Cucumis 
sativus extract. The obtained results confirmed the anti-inflammatory activity of both 
extracts on endothelial cells, suggesting a potential pharmaceutical application for 
cardiovascular health. However, B. serrata extracts showed also cytotoxicity or 
proliferative stimulation, depending on the dose and the formulation. Denying the 
common belief that herbal products are safe because they are natural, attention should be 
paid when these herbal supplements are used in human and animal phytotherapy, alone 
or as adjuvant of conventional therapies. 
The second model was the canine osteosarcoma cell line (D-17) employed to evaluate the 
cytotoxicity and anti-proliferative effects of a hydroalcoholic extract of Artemisia annua, 
compared to its main active compound artemisinin, used as a reference. Dogs are unique 
animal models of cancer in that they generally experience spontaneous disease and share 
significant clinical and biological similarities with humans. The preliminary results 
confirmed the cytotoxicity of A. annua also in this canine tumour cell line. 
Hydroalcoholic extract showed much more potent cytotoxic effect than pure artemisinin, 
inducing a significant increase of G2/M phase of cell cycle. A complete characterization 
of the phytoextract will be necessary to accurately quantify artemisinin and better 
4 
 
understand the possible plant compounds that act synergistically for the final cytotoxic 
effect. 
In conclusion, the in vitro models based on animal cell cultures have shown to be a 
significant preclinical tool, contributing to the application of the "Replacement" principle. 
Finally, this study confirmed the importance of evidence-based research in phytotherapy 





















Traditional medicine is “the knowledge, skill, and practices based on the theories, beliefs, 
and experiences indigenous to different cultures, whether explicable or not, used in the 
maintenance of health as well as in the prevention, diagnosis, improvement or treatment 
of physical and mental illness” (WHO, 2018). In traditional medicine, the attention is 
oriented on the whole condition of the individual, rather than on the particular disease, 
and the use of herbs is the most important part of all traditional medicines (Schmidt et al., 
2008; Wachtel-Galor and Benzie, 2011).  
Traditional Chinese medicine (TCM) has an ancient history of more than 3000 years and 
is the most important example of traditional medicines (Xutian et al., 2009). The oldest 
known herbal text in the world is The Devine Farmer’s Classic of Herbalism, compiled 
about 2000 years ago in China and many herbal pharmacopoeias and monographs on 
individual herbs were developed through these accumulated knowledges.  
During the past 100 years, the development and production of chemically synthesized 
drugs have revolutionized health care in most parts of the world. However, particularly 
in developing countries, many populations still rely on traditional practitioners and herbal 
medicines for their primary care. In China, traditional medicine accounts for around 40% 
of all health care delivered and more than 90% of general hospitals have units for 
traditional medicine. In Africa up to 90% and in India up to 70% of the population depend 
on traditional medicine for their primary care (WHO, 2005). However, during the last two 
decades, the use of traditional medicine is not limited to developing countries, but the 
public interest in natural remedies has increased considerably even in industrialized 
countries, with expanding use of botanicals. In the United States, around 38% of adults 
and 12% of children used some form of traditional medicine in 2007 (Barnes et al., 2008; 
Wachtel-Galor and Benzie, 2011).  
Principally, herbal medicines are used for health promotion and therapy of chronic 
conditions. However, the use of traditional remedies increases when conventional 
medicine is ineffective in the treatment of diseases, such as in advanced cancer and in 
new infectious diseases. Moreover, traditional medicines are widely perceived as natural 
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and safe, and, for this reason, not toxic. This is not necessarily true, especially when herbs 
are taken together with prescription drugs, medicines over-the-counter, or in mixtures 
with other herbs (Canter and Ernst, 2004; Cohen and Ernst, 2010; Wachtel-Galor and 
Benzie, 2011). 
Traditional and Complementary Medicine (T&CM) is increasing and expanding, 
particularly with the opportunity to buy natural products on line in Internet. The T&CM 
field now plays an important role in the economic development of many countries. At the 
same time, with prevailing current global financial constraints, use of T&CM for self-
health care, health promotion and diseases prevention may actually reduce healthcare 
costs (WHO, 2013). The commercial value of the ethnobotanical market is constantly 
expanding and should not be underestimated. For example, in 1995, in Germany the total 
turnover of non-prescription-bound herbal medicines in pharmacies was equal to almost 
30% of the total turnover of non-prescription-bound medicines, and in the United States, 
the annual retail sales of herbal products was estimated to be US$ 5.1 billion (Wachtel-
Galor and Benzie, 2011). 
Currently, herbal products are employed for the treatment of chronic and acute conditions 
and various disorders such as cardiovascular diseases, asthma, lung diseases, depression, 
inflammation, and to boost the immune system. In 2003, in China, traditional herbal 
medicines played a strategic role to contain and treat severe acute respiratory syndrome 
(SARS) and in Africa, a traditional herbal medicine, the Africa flower, has been used for 
decades to treat wasting symptoms associated with HIV (Tilburt and Kaptchuk, 2008). In 
Europe, Germany and France are countries leading in the use of herbal medicines and in 
most developed countries, one can find essential oils, herbal extracts or herbal teas being 
sold in pharmacies with conventional drugs (Wachtel-Galor and Benzie, 2011). 
Plants are rich in a variety of compounds. Many of these are secondary metabolites 
including aromatic substances, phenols or their oxygen-substituted derivatives such as 
tannins (Hartmann, 2007). Most of these compounds have antioxidant properties. Natural 
products and plant constituents can be used directly as therapeutic agents, but 
ethnobotanicals are important for pharmacological research and drug development 
because they can be used  as starting materials for the synthesis of drugs or as models for 
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pharmacologically active compounds (Li and Vederas, 2009). About 200 years ago, 
morphine, the first pharmacologically active pure compound, was obtained from opium 
extracted from seeds pods of the poppy Papaver somniferum. This discovery showed that 
drugs can be purified from plants and administered in precise dosages (Hartmann, 2007). 
The discovery of penicillin enhanced this method and the active compounds obtained 
from the plants continued to increase (Li and Vederas, 2009). With this trend, products 
derived from plants and natural sources (such as fungi and marine microorganisms) or 
analogues inspired by them have contributed greatly to the commercial drug production. 
Examples include the cardiac stimulant digoxin obtained from foxglove (Digitalis 
purpurea); antibiotics (e.g., penicillin, erythromycin); salicylic acid, a precursor of 
aspirin, derived from willow bark (Salix spp.); reserpine, an antipsychotic and 
antihypertensive drug obtained from Rauwolfia spp.; and antimalarials such as quinine 
derived from Cinchona bark and lipid-lowering agents (e.g., lovastatin) obtained from a 
fungus (Li and Vederas, 2009; Schmidt et al., 2008). Also, more than 60% of cancer 
therapeutics on the market or in testing are derived or inspired by natural products. For 
treatment of cancer, over 70% of drugs approved worldwide are based on natural products 
or mimetics, many of which were improved with combinatorial chemistry. Cancer 
therapeutics from plants include paclitaxel, isolated from the Pacific yew tree; 
combretastatin, derived from the South African bush willow; camptothecin, derived from 
Camptotheca acuminata is used to obtain irinotecan and topotecan. It is also estimated 
that about 25% of the drugs prescribed worldwide are derived from plants and 121 active 
compounds are in use (Sahoo et al., 2010). Between 2005 and 2007, 13 drugs obtained 
from natural products were approved in the United States. More than 100 natural product-
based drugs were in clinical studies (Li and Vederas, 2009), and of the total 252 drugs in 
the World Health Organization’s (WHO) essential medicine list, 11% are exclusively of 
plant origin (Sahoo et al., 2010; Wachtel-Galor and Benzie, 2011). 
Regulations, quality, safety, and scientific evidence 
WHO has recognized the important contribution of traditional medicine to provide 
essential care and developed “The WHO Traditional Medicine Strategy 2014 –2023” 
(WHO, 2013). In 1989, the U.S. Congress established the Office of Alternative Medicine 
within the National Institutes of Health to encourage scientific research in the field of 
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traditional medicine (https://nccih.nih.gov/) and in the same year, the European Scientific 
Cooperative on Phytotherapy (ESCOP) was founded with the aim of advancing the 
scientific status and harmonization of phytomedicines at the European level 
(http://escop.com/). 
The increasing interest and great expansion of traditional medicines worldwide, bring 
with them important challenges. There are international diversity and national policies 
regarding the regulation of the production and use of herbal products, consequently there 
is need to improve quality, safety, and scientific evidences of botanicals in relation to 
health claims (Sahoo et al., 2010; WHO, 2005). 
In Europe, the Directive 2001/83/EC released in 2001 by the European Parliament and 
by the Council of Europe provides the Community code relating to medicinal products 
for human use. This Directive shall apply to industrially produced medicinal products for 
human use intended to be placed on the market in Member States, including herbal 
medicines (Directive 2001/83/EC, 2001). However, in 2004 the European Parliament and 
Council amended Directive 2001/83/EC by enacting Directive 2004/24/EC, providing the 
guidelines for the use of traditional herbal medicinal products (Directive 2004/24/EC, 
2004). In this directive a simplified registration procedure “traditional use registration” is 
established for those herbal medicinal products, for which a “bibliographical or expert 
evidence to the effect that the medicinal product in question, or a corresponding product 
has been in medicinal use throughout a period of at least 30 years preceding the date of 
the application, including at least 15 years within the Community” (Directive 
2004/24/EC, 2004). After demonstrating the necessary number of years of traditional safe 
use, the herbal products can enter in the European pharmaceutical regime with the 
simplify procedure called "registration of traditional use". Directive 2004/24/EC also 
established the Committee on Herbal Medicinal Products (HMPC) at the European 
Medicines Agency (EMA). The HMPC is responsible for compiling and assessing 
scientific data on herbal substances, preparations and combinations, to support the 
harmonisation of the European market. Moreover, the HMPC establishes European 
monographs covering the therapeutic uses and safe conditions of well-established and/or 
traditional use for herbal substances and preparations (HMPC, 2004). 
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During the years, herbal medicine has been commonly used for enhancement of the 
quality of life, health promotion and for treatment and prevention of diseases.  The holistic 
approach to health care makes herbal medicine very attractive to consumers, but it also 
makes scientific evaluation very difficult because so many factors must be considered. 
Herbal products are in widespread use and although they are believed as safe, they are 
often used in mixture and are obtained from plant sources with their own variability in 
species, growing conditions, and biologically active constituents. Herbal extracts may be 
adulterated, contaminated and may contain toxic compounds. The quality control of 
herbal medicines has a direct impact on their safety and efficacy but there is a lack of 
evidence-based research to assess quality, safety and effectiveness of many commercial 
products (Ernst et al., 2005; Wachtel-Galor and Benzie, 2011). As a consequence, these 
data are available on the molecular composition and quality of many herbal products not 
only due to lack of government requirements or international policies but also due to lack 
of adequate or accepted analytical techniques for characterizing and evaluating traditional 
medicines. Though the wide popularity of herbal supplements and botanicals, some 
herbal products on the market are likely to be of low quality and efficacy, and do not 
contain the effective claimed active substances, even if the same herb has been shown to 
have a biological activity in controlled studies using high-quality phytoextract (Wachtel-
Galor and Benzie, 2011). 
The most important advantage of herbal medicines over conventional drugs with a well 
characterized molecular profile is the presence of multiple active compounds that together 
can provide a synergic effect that may not be achievable by any single compound, but it 
is the result of the complete phytocomplex. Ideally, the composition of the botanical 
extract must be standardized and free of any potential hazards, and plants should be grown 
under controlled conditions, because the environment can significantly affect the 
phytochemical profile and the efficacy of the botanical product. In practice, the situation 
is very different. Herbal extracts contain hundreds of compounds, many of which are 
unknown and chemical fingerprinting is in its early stages and is lacking for most herbs. 
This makes standardization of botanicals difficult, although few of them can be produced 
with a standardized amount of a key component or class of components. However, even 
when such key compounds have been identified and a standard content is agreed or 
suggested, there is no guarantee that individual commercial herbal products actually 
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contain these essential components and in the claimed concentration (Wachtel-Galor and 
Benzie, 2011). 
Research into quality, safety, biological activity and clinical efficacy of the different 
herbal medicines of common usage is needed. Newly emerging scientific approaches, 
genomic testing and chemical fingerprinting techniques using hyphenated testing 
platforms are now available for definitive authentication and quality control of herbal 
products (Patel et al., 2010; Wachtel-Galor and Benzie, 2011).  
The values of Evidence-based Medicine and Evidence-based Research (Kelly et al., 2015; 
Sackett et al., 1996; Timmermans and Mauck, 2005) should also be applied to herbal 
medicine. Research is also needed to obtain science-based information on dosage, 
contraindications and effectiveness of most natural compounds. Herbal products can be 
safely used in human and animal phytotherapy only applying scientific principles. 
Veterinary herbal medicine 
Since ancient times, with a traditional history that can be traced back over millennia, 
herbal medicines were used also in animal care. In the rural areas worldwide, the 
veterinary medicine deals with knowledge, methods, practices, skills and beliefs about 
caring for their livestock. In some remote areas, people have great undocumented 
traditional knowledge about animal diseases, herbal treatments, formulations, etc., but 
most of these traditional treatments were limited to restricted populations (Rastogi et al., 
2015). In 1998, McCorkle defined Ethnoveterinary Medicine (EVM) as: “The holistic, 
interdisciplinary study of local knowledge and its associated skills, practices, beliefs, 
practitioners, and social structures pertaining to the healthcare and healthful husbandry 
of food, work, and other income-producing animals, always with an eye to practical 
development applications within livestock production and livelihood systems, and with 
the ultimate goal of increasing human well-being via increased benefits from 
stockraising” (McCorkle and Martin, 1998). However, the most studied element of EVM 
is veterinary ethnopharmacopoeia, especially the use of botanicals. These knowledge and 
skills are hundreds or even thousands of years old. Classic cases include Ayurveda in 
India (Rastogi et al., 2015) and herbal medicine in China (Lin and Panzer, 1994; Xie and 
Eckermann-Ross, 2012). Ethnoveterinary is practised in several parts of the world, in 
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Africa (Assefa and Bahiru, 2018; Gabalebatse et al., 2013; McGaw and Eloff, 2008; 
Ndhlovu and Masika, 2013), in Asia (Khattak et al., 2015; Rastogi et al., 2015; Suroowan 
et al., 2017), in America (Lans, 2016) and also in Europe (Mayer et al., 2014; Piluzza et 
al., 2015).  
In recent years, the increasing attention over the spread of antibiotic resistance, has raised 
the interest in phytotherapy, with the aim to reduce the use of antibiotics in livestock. 
Veterinary herbal medicinal products are not authorised centrally in the Europe, but by 
the national governments. Nevertheless, it is permitted to sell feed additives containing 
plant material in different formulations, with claims concerning optimisation of nutrition, 
support and protection of the physiological conditions, unless they do not contain a claim 
declaring that they will prevent, treat or cure a disease. Due to their easy access, botanical 
products are primarily sold as feed additives, and they may be used as presumed remedies 
(Blanco-Penedo et al., 2018).  
Scientific information regarding veterinary phytotherapy is rare. Research is needed to 
validate efficacy also in veterinary herbal medicine (Mayer et al., 2014). Applying 
analytical methods, such as metabolomics, could help to better identify the chemical 
composition, and ensure standardisation and safety of the herbal products. Recent 
development of high-throughput and “omics” technologies might accelerate studies of the 
mechanisms underlying the biological activity and, therefore, support the effective use of 
these compounds (Blanco-Penedo et al., 2018). 
An adaptation of the European legislation would potentially make it possible to register 
traditional veterinary herbal medicinal products through a simplified registration 
procedure or support the registration as health-supporting feed supplements (zootechnical 
feed additives). Some experts suggested to harmonize veterinary and human regulations, 
adapting the requirements for safety assessments to the specific circumstances 
surrounding botanicals that have been used for a long time and that are included in 




Figure 1. Disciplines and impact flows related with the main challenges in phytotherapy (Blanco-Penedo 
et al., 2018). 
Only coordinated and sustained efforts by all players in animal health care as well as 
developers of regulatory framework will allow possibilities to release the potential 




In vitro models as alternatives to animal testing 
The Principles of the “3Rs” 
The publication of "The Principles of Humane Experimental Technique" by W.M.S. 
Russell and R.L. Burch in 1959 (Russell and Burch, 1959) marks the birth of the principle 
of the “3Rs”.  
The authors proposed the principles of Replacement, Reduction and Refinement (the 
“3Rs”) as the key strategies of a systematic framework aimed at achieving the goal of 
human experimental techniques. Russell and Burch saw replacement as the ultimate goal 
for laboratory animal based research, education and testing, with the other two, reduction 
and refinement, being more readily achievable in the short term (European Commission 
Environment DG, 2016). 
Replacement 
The authors proposed to distinguish relative and absolute replacement. In relative 
replacement, animals are still required, though in actual experiment they are exposed, 
probably or certainly, to any distress at all. In absolute replacement, animals are not 
required at all at any stage of the experiments. Consequently, good absolute replacement 
may be regarded as the final ideal of replacement. But when relative replacement is 
combined with great reduction, as in the use of tissue culture, it may be very welcome 
indeed, and such developments are among the most important in the whole progress of 
research.  
The first option is the case of non-recovery experiments on living and intact but 
completely anesthetized animals. In relation to contingent inhumanity, it is important that 
the anaesthesia is general and sufficiently deep, and its time-course properly synchronized 
with the treatment. The second one is the case of experiments in which animals are still 
required, but only to furnish preparations after being painlessly killed. This already 
constitutes a further advance. The remaining types of relative replacement involve work 
on the isolated cells, tissues, or organs of vertebrates.  
15 
 
Tissue culture represents a bridge between relative and absolute replacement, in which 
vertebrate animals are not required at all. Turning to absolute replacement, four main 
subdivisions may be distinguished: the use (outside the vertebrate body) of metazoan 
endoparasites, higher plants, microorganisms (protozoa, bacteria, molds, etcs.), and non-
living physical and chemical systems (Russell and Burch, 1959). 
Reduction 
The concept of reduction extends to any approach that will result in fewer animals being 
used to achieve the same objective, including maximising the information obtained per 
animal, reducing the number of animals used in the original procedure and/or limiting or 
avoiding the subsequent use of additional animals. 
By performing more than one procedure on the same animals it is possible to reduce the 
number of animals used, where this does not decrease the scientific objective or result in 
poor animal welfare. However, the benefit of reusing animals should always be balanced 
against any adverse effects on their welfare, considering the lifetime experience of the 
individual animal. As a result of this potential important conflict, the reuse of animals 
should be considered on a case-by-case basis (European Commission Environment DG, 
2016). 
Refinement 
Today, the term refinement applies to all aspects of animal use, from the time the 
experimental animal is born until its death and signifies the modification of any procedure 
or husbandry and care practice to minimise pain, suffering, distress or lasting harm and 
enhance its welfare. 
When an animal experiences pain, suffering or distress, there are often accompanying 
physiological, immunological and behavioural changes which may increase the 
variability of scientific results. Therefore, refinement is also likely to improve data quality 




The “3Rs” in European legislative framework 
The protection of animal rights and in particular those used for scientific purposes has 
long been a subject of interest for the Council of Europe. In 1986, the first milestone was 
achieved, when the European Convention for the Protection of Vertebrate Animals used 
for Experimental and Other Scientific Purposes was open for signature. This Convention 
is designed to reduce both the number of experiments and the number of animals used for 
scientific purposes and it encourages research without animal use, except where there is 
no validate alternative and it promotes research into alternative methods. The Council of 
Europe Convention paved the way for the EU’s Directive 86/609/EEC, adopted in 1986, 
as the provisions in it are based on the Convention (European Directorate for the Quality 
of Medicines - EDQM). 
However, the present Directive 2010/63/EU on the protection of animals used for 
scientific purposes, for the first time in EU legislation spells out the principle of the “3Rs” 
and makes it a firm legal requirement. The principles of Replacement, Reduction and 
Refinement must be considered systematically at all times when animals are used for 
scientific purposes in the EU. Under the Directive, the term "scientific purposes" covers 
all uses of animals for the purposes of basic, translational and applied research, regulatory 
testing and production as well as for the purposes of education and training. 
Furthermore, the Directive ensures that its application goes beyond that of the original, 
narrower interpretation of the “3Rs” only in the context of choice of methods. The 
Directive enlarges the Refinement also to cover all animal breeding and care, that is, to 
ensure refinement during housing, breeding and care even if animals are not undergoing 




What are alternative approaches? 
The term ‘alternatives’ in this context includes all assays, tests, methods, techniques, 
tools, strategies and approaches etc. that contribute to the practical implementation of the 
“3Rs”. That is: 
• to obtain the required information without the use of live animals; 
• to reduce the numbers of animals whilst obtaining the same level and quality of 
information; 
• to refine the use of live animals so as to cause less pain, distress or suffering, or 
improve the welfare of the animals. 
Alternative methods provide opportunities to extend the principles of "3Rs", but, at the 
same time, they aim to develop better and more predictive scientific tools to protect 
human and animal health and the environment (European Commission Environment DG, 
2016). 
The European Commission's involvement in activities targeted to the validation of 
alternative approaches to animal testing started in 1991, with the launch of ECVAM (the 
European Centre for the Validation of Alternative Methods), hosted by the Joint Research 
Centre located in Ispra, Italy. The European Union Reference Laboratory for alternatives 
to animal testing (EURL ECVAM) has been formally established in 2011, due to the 
increasing need for new methods to be developed and proposed for validation in the 
European Union.  
EURL ECVAM has a long tradition in the validation of methods which reduce, refine or 
replace the use of animals for safety testing and efficacy/potency testing of chemicals, 
biologicals and vaccines. Research laboratories are able to submit to EURL ECVAM for 
scientific validation the alternative methods to animal testing that they have developed. 
EURL ECVAM also promotes the development and dissemination of alternative methods 




In July 2013, the European Commission announced the creation of European Union 
Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL) in 
response to the provision of Directive 2010/63/EU on the protection of animals used for 
scientific purposes which requests that EU Member States assist the European 
Commission in the validation of alternative methods. Currently there are a total of 37 
members of EU-NETVAL, selected against pre-defined eligibility criteria (including the 
European Commission's own in vitro GLP test facility operated by EURL ECVAM, 
which coordinates the network) and endorsed by the National Contact Points.  
EU-NETVAL's mission is to provide support for EURL ECVAM validation studies that 
serve to assess the reliability and relevance of alternative methods that have a potential to 
replace, reduce, or refine the use of animals for scientific purposes.  
In addition to the wide range of techniques and capabilities, the network offers an 
opportunity to share knowledge and to collaborate for the promotion of the development 
and use of alternative approaches. The knowledge and expertise contained within EU-
NETVAL is extremely valuable for translating scientific innovation in the “3Rs” into 












Plants, herbs and ethnobotanicals have been used since ancient times and are still used 
throughout the world for health promotion and treatment of diseases, not only in human 
medicine but also in veterinary medicine. In recent years, the increasing interest in the 
use of herbal medicine involves important challenges. The first is the international 
diversity of policies concerning the regulation of production and use of herbs, their quality 
and safety in relation to health claims. Consequently, the second is the need of research 
to obtain scientific evidence on the molecular basis of biological activity of traditional 
remedies.  
The current European regulation on the protection of animals used for scientific purposes 
(Directive 2010/63/EU), for the first time in EU legislation spells out the principle of the 
“3Rs” and promotes the development of alternative methods.  
The main purpose of this research project is the evaluation of the biological activity of 
selected anti-inflammatory and anticancer natural phytoextracts in in vitro cellular 
models.  
Considering swine an important animal model for translational medicine, an 
inflammatory model developed in primary culture of porcine aortic endothelial cells 
(pAECs) induced by LPS was chosen. The cytotoxicity and the anti-inflammatory activity 
of two traditional Ayurvedic remedies, Boswellia serrata and Cucumis sativus extracts 
was evaluated using this in vitro model. 
Naturally occurring tumours in dogs have many clinical and biological similarities to 
human cancers and make the dog an important spontaneous animal model in comparative 
medicine. Therefore, the canine osteosarcoma cell line (D-17) was chosen to evaluate the 
cytotoxicity and anti-proliferative effects of a hydroalcoholic extract obtained from 
Artemisia annua L., used for centuries in Chinese Traditional Medicine as antimalarial 













Translational research: swine as animal model 
The European Society for Translational Medicine (EUSTM) defines Translational 
Medicine as an “interdisciplinary branch of the biomedical field supported by three main 
pillars: bench side, bedside and community. The goal of Translational Medicine is to 
combine disciplines, resources, expertise, and techniques within these pillars to promote 
enhancements in prevention, diagnosis, and therapies” (Cohrs et al., 2015). 
The use of animal models in preclinical research is pivotal to bridge the translational gap 
to the clinic field (Denayer et al., 2014). The species of origin of an in vitro model is also 
of great importance and may increase the translational impact of a study. Ideally, the best 
choice would be of human origin; however, this has its own limitations due to sample 
availability, in addition most available samples coming from diseased tissue with altered 
phenotypes. To address this, swine could be a suitable alternative. (Olayanju et al., 2018). 
The pig has several distinct advantages that have made this species a useful translational 
animal model for human research. In particular, there are important anatomic, 
physiological, metabolic and genetic similarities to human beings. As a consequence, pig 
is deservedly one of the most important animal model for preclinical studies (Gonzalez 
et al., 2015; Groenen et al., 2012; Perleberg et al., 2018; Prather, 2013; Stricker-Krongrad 
et al., 2016). 
In 2012, the Swine Genome Sequencing Consortium sequenced the genome of Sus scrofa 
and is continually characterizing and updating it (Groenen et al., 2012). The achievement 
of the complete swine genome sequence project has greatly accelerated the process of 
gene targeting and identification of conserved genes, confirming the relevance of pig as 
a preclinical translational model (Perleberg et al., 2018; Prather et al., 2013; Walters et 
al., 2017). The swine genome has 18 chromosome pairs and 2 sex chromosomes of 
approximately 2.7 Gb, about 7% smaller than the human genome but the overall similarity 
of the transcribed swine genome is approximately 85%. In comparison, canine and mouse 
genomes are 14% smaller than the human one. Naturally occurring mutations associated 
with human diseases have been identified in homologous regions of porcine genome 
showing phenotypes comparable to those of humans (Schomberg et al., 2016).  
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Despite the important need of husbandry, many advantageous practical factors, such as 
breeding characteristics, make pigs an important animal model for human research. Pigs 
mature relatively quickly for a large species (6-7 months), have a short gestation period 
(∼114 days) and produce large litters (∼10 piglets per litter), depending on the breed. 
Centuries of pig domestication have established suitable housing conditions, including 
specific pathogen-free conditions, which require only minor adaptation for research 
(Meurens et al., 2012; Perleberg et al., 2018). Furthermore, pigs have advantages over 
other animal models in that ethical and societal concern presumably is lower for 
utilization of a farm animal as a research model in comparison with companion animals 
and nonhuman primates (Prather et al., 2013; Schomberg et al., 2016).  
In particular, the use of miniature pigs in research has been continuously expanding for 
over a decade. Beyond genetic, anatomic, and physiologic similarities of the conventional 
swine breeds to humans, miniature pigs also have the additional advantages of size and 
slower growth curves like humans.  At full maturity, conventional breeds can reach 249 
- 306 kg and pose important needs in husbandry and handling in the biomedical research 
setting. In contrast, at equivalent maturity, miniature swine weigh 68 - 91 kg, the weight 
of an average human male. Their size also allows for the use of medical equipment and 
procedures that are used in human clinical settings, allowing researchers to employ state-
of-the-art medical innovations in research, while giving direct translatability of 
experimental knowledge gained to humans (Schomberg et al., 2016; Stricker-Krongrad 
et al., 2016). 
The intestinal microbial ecosystem plays an important role in maintaining health. Pigs are 
human-sized omnivorous with nutritional requirements comparable to humans and share 
similar metabolic and intestinal physiological processes. This likely contributes to their 
comparable mucosal barrier physiology and enteric microbiota, as well as susceptibility 
to selected enteric pathogens, in fact pigs also exhibit similar intestinal syndromes to 
humans. Similarities in the intestinal microbial ecology between pigs and humans have 
made the pig an important non primate animal model for research on dietary modulation 
of intestinal microbiota as a therapeutic or preventive tool (Gonzalez et al., 2015; Heinritz 
et al., 2013). 
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Moreover, pigs are the species of choice as a model for highly prevalent human diseases: 
diabetes, metabolic syndrome, obesity and cardiovascular diseases (Bassols et al., 2014; 
Swindle et al., 2012). In particular, the surgical community has recognized swine to be 
an excellent anatomical and physiological model for the human cardiovascular system 
since decades. The pig heart, coronary vessels, vasculature, and blood flow are very 
similar to those of humans, and overall, pigs are better suited to study cardiovascular 
diseases than rodent and canine models. Atherosclerosis and myocardial infarction can 
be induced in swine by providing diets with nutrient compositions that are known to 
increase the risk for cardiovascular disorders in humans (Prather et al., 2013; Swindle et 
al., 2012). 
 
Figure 2. Pig as a model in biomedical proteomics research (Bassols et al., 2014). 
Although it is an excellent model in its natural state, pig is even more attractive for the 
biomedical community due to the possibility to obtain genetic engineered animals for 
specific human diseases. The application of genetic modification technology to pigs has 
greatly increased their value to biomedicine. Advancements in “gene editing” (e.g., 
CRISPR/Cas9 system) now allow researchers to build upon the human-like genome 
template and replicate genetic conditions responsible for human diseases and improve 
histocompatibility of swine organs for xenotransplantation. The most promising and 
clinically relevant genetically modified porcine models of human diseases for 
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translational biomedical research include cardiovascular diseases, cancers, diabetes 
mellitus, Alzheimer’s disease, Huntington’s disease, cystic fibrosis, retinitis pigmentosa, 
spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (Fig. 3) (Perleberg et 
al., 2018; Prather et al., 2013; Walters et al., 2017).  
 
Figure 3. Organ systems for which genetically engineered pigs have been created (Prather et al., 2013). 
In the last decade, swine has been considered the most suitable animal model in the 
development of stem cell-based therapy, regenerative medicine and transplantation. 
Porcine Mesenchymal Stem Cells (pMSCs) were isolated from several sources (bone 
marrow, adipose tissue, peripheral blood, aorta, coronary vessels, etc.) and share 
differentiation potential, cell surface markers and gene expression with human MSCs. 
Despite immense proliferation and differentiation potential of pMSCs, their low 
immunogenicity, immunosuppressive and immunomodulatory properties make them a 
promising candidate for cellular therapy (Bharti et al., 2016; Casado et al., 2012; Zaniboni 
et al., 2015, 2014). Recently, it has been demonstrated that, in 56% of cases, the pig is the 
large animal of choice for regenerative medicine in the areas of cardiovascular, 
orthopaedic and wound-healing research. Preclinical trials for toxicology and 
regenerative medicine products have traditionally relied on rodent models, but the pig 
was more in recent years (Walters et al., 2017).  
With an increasing need for swine models, it is essential that the genomic tools, models 
and services be readily available to the scientific community. In 2003, the US National 
Institutes of Health (NIH) at the University of Missouri funded the National Swine 
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Resource and Research Center (NSRRC). It is a facility with the aim to provide high-
quality biomedical swine models to the scientific community (Walters et al., 2017). 
Porcine Aortic Endothelial Cells (pAECs) 
The endothelium is a cellular monolayer that lines the lumen of blood vessels and plays 
an important physiological role in vascular homeostasis. Moreover, the endothelium is 
responsible for different functions including the modulation of vascular tone, the vascular   
permeability, the maintenance of blood fluidity, the regulation of inflammation and 
immune response, the prevention of thrombosis and overall the maintenance of vessel 
integrity. Endothelium impairment is a complex pathophysiological event that includes 
both the increased activation of endothelial cells and the onset of endothelial dysfunction 
(Chistiakov et al., 2015; Incalza et al., 2018). 
The endothelium is more than inert blood vessel lining tissue, in fact endothelial cells  are 
active players in the formation of new blood vessels both in health and diseases by an 
active and regulated phenomenon of angiogenesis (Eelen et al., 2018).  
The vascular endothelium is the first functional organs that develops during 
embryogenesis and matures into a closed cardiovascular system to conduct vasculature 
blood flow through an intricate network of large- to medium-size vessels extending into 
micrometer-size capillaries. During early embryo development, a primitive vascular 
plexus is formed in a process termed vasculogenesis. This primitive plexus subsequently 
undergoes substantial remodelling by vessel intussusception whereby a pre-existing 
capillary splits in two adjacent vessels or by sprouting angiogenesis whereby a new 
capillary sprouts of a pre-existing vessel. Sprouting angiogenesisis the more frequently 
studied and better-understood form of vessel formation, and typically entails a series of 
highly orchestrated processes driven by identified pro-angiogenic stimuli (Fig. 4) (Eelen 
et al., 2018).  
On the other hand, pathological excessive angiogenesis causes many diseases including 
cancer, pulmonary arterial hypertension and many eye diseases characterized by ocular 




Figure 4. General concepts in angiogenesis: tip versus stalk specification and anastomosis. A: in 
sprouting angiogenesis, a pro-angiogenic growth factor gradient induces tip and stalk cell formation in a 
pre-existing vessel to form a new sprout. B: newly formed sprouts from neighboring vessels meet and fuse 
through a process termed anastomosis (Eelen et al., 2018). 
Furthermore, endothelial cells have a key position in the beginning, progression, control 
and resolution of the vascular dysfunction (Cahill and Redmond, 2016; Chistiakov et al., 
2015; Endemann and Schiffrin, 2004; Jamwal and Sharma, 2018). 
Endothelial activation is the first step observed and is defined as a pro-inflammatory, pro-
coagulant and pro-thrombotic state of the endothelial cells, characterized by the 
expression of cell-surface adhesion molecules required for the recruitment and attachment 
of inflammatory cells (Liao, 2013). Endothelial activation is induced by cytokines 
secreted by tissues and organs under endogenous and exogenous pro-inflammatory 
stimuli, such as lipopolysaccharide (LPS). The phenotype of activated endothelial cells 
promotes phenomena of vasoconstriction, leukocyte adhesion, coagulation and 
thrombosis. This change involves the up-regulation of pro-inflammatory genes, including 
secretion of inflammatory cytokines and chemokines. If the pro-inflammatory status is 
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not counterbalanced by the synthesis of protective molecules, the endothelial activation 
converts into the endothelial dysfunction and then in the vascular disease (Incalza et al., 
2018; Leligdowicz et al., 2018; Sprague and Khalil, 2009). 
The endothelial dysfunction (ED) is thus defined as an imbalance in the production of the 
vasodilator and vasoconstrictor factors, which predisposes the vasculature toward a pro- 
thrombotic and pro-atherogenic phenotype, characterized by vasoconstrinction, leukocyte 
adhesion, platelet activation, mitogenesis, pro-oxidation, impaired coagulation, vascular 
inflammation, atherosclerosis and thrombosis. Endothelial dysfunction has been linked to 
many diseases, including atherosclerosis, diabetes mellitus, coronary artery diseases, 
hypertension and hypercholesterolemia (Incalza et al., 2018). 
Primary cell cultures are increasingly used as a significant tool in cellular and molecular 
biology. Since primary cells are non-transformed and non-immortalized, they faithfully 
reproduce in vivo phenotype and reach more physiologically significant results. In 
particular, primary cultures of endothelial cells are important for the studies of vascular 
dysfunction in cardiovascular diseases. 
At the BMC Laboratory (Cellular and Molecular Biochemistry and Biotechnology) in the 
Department of Veterinary Medical Sciences of the University of Bologna, a method for 
the isolation of endothelial cells from porcine thoracic aorta was developed (Bernardini 
et al., 2005).  
Briefly, thoracic aortic traits were collected from adult pigs at a local slaughterhouse in 
accordance with the “Replacement” of principle of the “3Rs” (Russell and Burch, 1959) 
inserted in the European Directive 2010/63 / EU on the protection of animals used for 
scientific purposes (Directive 2010/63/EU, 2010). After collection, aortas were 
transferred to the laboratory within 1 hour on ice. Then aortas were washed in sterile 
saline solution added with ampicillin (1 mg/ml) (Sigma Alderich, St Louis, MO, USA) 
and amphotericin B (1%) (Gibco-Life technologies Carlsbad CA, USA), then they were 
washed in sterile Dulbecco Phosphate Buffer Solution (DPBS, Gibco-Life technologies) 
added with antibiotics/antimycotics solution (10%) (Gibco-Life technologies). After 
ligation of all arterial side branches (Fig. 5A), aortas were cannulated with modified 
syringe cones and silicone tubes to set up a closed system (Fig. 5B). The vessels were 
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gently flushed with DPBS to remove residual blood (Fig. 5C), then they were filled with 
DPBS added with 0.2% collagenase (Sigma Alderich) and clamped at both ends. After 
20 minutes of incubation at 37 °C, the collagenase solution was collected, and the vessels 
were washed with DPBS with 10% fetal bovine serum (FBS) (Gibco-Life technologies). 
The solutions were centrifuged at 800 x g for 10 minutes. The cellular pellet was 
resuspended in 1 mL human endothelial basal growth medium (Gibco-Life technologies) 
supplemented with 5% FBS and 1% antibiotics-antimycotics (Gibco-Invitrogen). Cell 
number and viability (85–90%) were determined using a Burker chamber under a phase-
contrast microscope. Approximately 3 X 105 cells were placed in T-25 primary tissue 
culture flasks (T25-Falcon, Becton-Dickinson, Franklin Lakes, NJ, USA) in a 5% CO2 
atmosphere at 38.5 °C. The cells were maintained in a logarithmic growth phase by 
routine passages every 2–3 days at a 1:3 split ratio. To confirm their endothelial origin, 
cultured cells were checked by immunocytochemistry for endothelial cell markers: CD31, 
VIII factor and VE-Caderine. Then cells were expanded till 20th passages. 
 
Figure 5. Isolation of endothelial cells from porcine thoracic aorta. (A) ligation of all arterial side 
branches; (B) set up a closed system; (C) flushing with DPBS to remove residual blood and verify the 
closing of the system; (D) porcine Aortic Endothelial Cells (pAECs).  
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The complete procedure is available at this link 
http://www.portaledidatticovet.org/vet02/78-fisiologia/335-colture-cellulari.html 
Kindly acknowledgement to Professor Monica Forni for availability the video. 
In full accordance with the principle of “Replacement” (Directive 2010/63/EU, 2010; 
Russell and Burch, 1959), for more ethical use of animals in experimental testing, primary 
culture of porcine Aortic Endothelial Cells (pAECs) were successfully used in many 
different in vitro models.  
pAECs were used to study the vascular response to different physical, chemical and 
biological stimuli as in vitro model. In particular, the effects of the magnetic field 
(Bernardini et al., 2007), the toxic effects induced by the pollutant Tributyltin (TBT) 
(Botelho et al., 2015) and the alteration induced by components of the outer membrane 
of the spirochete Treponema denticola (OMT) (Bernardini et al., 2010a) were evaluated 
on pAECs. Moreover, pAECs were employed to develop an in vitro inflammatory model 
induced by lipopolysaccharide (LPS) (Bernardini et al., 2012, 2010b, 2005), preceding 
the endotoxic shock in vivo model and confirming swine as a relevant animal model for 
translational medicine (Forni et al., 2005; Zannoni et al., 2012, 2010). 
In this thesis, the activity of traditional remedies, used since ancient times in Ayurvedic 
medicine, was evaluated on in vitro inflammatory model induced by LPS. In particular, 
the anti-inflammatory activity of Boswellia serrata extracts (Bertocchi et al., 2018) and 





Boswellia is a relatively small genus belonging to the family of Burseraceae, with 28 
distinct species (The Plant List, 2013) distributed in Africa, in the Arabian Peninsula and 
in India. The best known are B. serrata Roxb. ex Colebr., native of India, B. frereana 
Birdw. and B. papyrifera (Caill. ex Delile) Hochst., from East Africa (Somalia and 
Ethiopia) and B. sacra Flueck, from the Arabian peninsula (Oman, Yemen and Southern 
Saudi Arabia) (Brendler et al., 2018; Iram et al., 2017; Shah et al., 2009).  
The taxonomic classification of Boswellia serrata Roxb. ex Colebr. is the following 
 Kingdom: Plantae  
• Subkingdom: Tracheobionta  
 Superdivision: Spermatophyta  
• Division: Magnoliophyta  
 Class: Magnoliopsida  
 Order: Sapindales 
 Family: Burseraceae  
 Genus: Boswellia  
 Species: Boswellia serrata Roxb. ex Colebr. 
B. serrata grows to a height of up to 15 m. It is deciduous and has a spreading crown with 
drooping branches (Fig. 6). It has a short bole (up to 5 m, sometimes longer) with an 
average girth of 1.2 - 1.8 m. The greyish-green to ashy or reddish bark is very thin, with 
the outer layer peeling off in thin, papery flakes. Leaves are variable in size, 20 - 45 cm, 
alternate and imparipinnate, predominantly at the end of branches. White flowers occur 
in axillary racemes, 10 - 20 cm long. The fruits are trigonous, three-valved drupes, with 




Figure 6. Indian frankincense, Boswellia serrata tree and a particular of exudate derived by incision of 
the bark of B. serrata tree.  
The dried exudate from the bark of B. serrata tree is an oleogum resin which is commonly 
known as Indian Frankincense, Indian olibanum, Incense or Salai guggal (Fig. 6). The 
dried gum appears in transparent, yellow brown fragrant tears around 5 cm long and 2 cm 
thick (Fig. 7). The tears are brittle and translucent with a waxy surface. The resin burns 
easily and produces a characteristic, resinous balsamic odour and taste (Brendler et al., 
2018). 
 
Figure 7. Frankincense olibanum resin (photo taken by Peter Presslein). 
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Incense was known to all the ancient civilisations and used in rituals and prayers to the 
gods. Frank “pure” incense and myrrh were the finest and most scarce substances used in 
religious ceremonies. Because of their rarity and great cost, the gifts of the Magi were a 
sign of wealth and sacrifice. Beyond that, there is medical evidence that gold, 
frankincense and myrrh were important for wound healing, used by many cultures and 
societies for thousands of years. Babylonians, Hindus, Buddhists, Shintoists, Greeks and 
Romans used incense in their ritualistic ceremonies. The oldest written document, which 
mentions frankincense as a drug is the papyrus Ebers. Remedies containing preparations 
from frankincense were used by Hippocrates, Celsus, Galenus and Dioskurides. The use 
of the oleogum resin of B. serrata (salai guggal) is described in Ayurvedic text books 
(Charaka Samhita, 1st - 2nd century AD and in Astangahrdaya Samhita, 7th century AD). 
Medical preparations containing the bark or the oleogum resin were used to treat a variety 
of diseases. These included diseases of the respiratory tract, diarrhoea, constipation, 
flatulence, central nervous diseases and others. Olibanum was still a remedy in the 
beginning of the 20th century in Europe. Thus, olibanum is mentioned in the supplement 
to the 6th edition of the German Pharmacopoeia, which appeared in 1926 (Ammon, 2006).  
The oleogum resin of different species of Boswellia contains more than 200 
phytochemicals. These compounds include 5-9% essential oil, 65-85% alcohol-soluble 
resin, and the remaining 21-22% is water-soluble gum (polysaccharidic fraction and 
polymeric substances).The content and composition of oleogum resin may vary from 
species to species depending upon age, quality of resin, geographical distribution (Al-
Yasiry and Kiczorowska, 2016; Ammon, 2006; Iram et al., 2017). The resin contains 
specific and characteristic pentacyclic and tetracyclic triterpenes. Among the pentacyclic 
triterpenes, boswellic acids are unique to Boswellia genus and responsible for many of 
the pharmacological effects (Fig. 8). Other compounds are tetracyclic triterpenic acids 
among which tirucallic acids were also shown to be biologically active (Ammon, 2006; 




Figure 8. Structures of major Boswellic acids (Gerbeth et al., 2013). 
 
The pharmacological effects of B. serrata have been mainly attributed to boswellic acids, 
especially 11-keto-b-boswellic acid (KBA) and acetyl-11-keto-b-boswellic acid 
(AKBA), which were proposed as selective 5-lipoxygenase (5-LO) inhibitors. However, 
other important targets of boswellic acids include topoisomerases, angiogenesis, and 
cytochrome p450 enzymes. Recently, other components of the phytocomplex, such as β-
boswellic acid (βBA), have been suggested as anti-inflammatory molecules, acting 
through inhibition of serine protease cathepsin G (catG) and microsomal prostaglandin E 




In the first paper six different B. serrata dry extracts and one hydroenzimatic extract were 
analysed. The first aim of this study was to perform a comparative analysis of AKBA 
content and in vitro antioxidant power of different dry and aqueous extracts of B. serrata 
gum resin as a tool for the evaluation of the quality of the extracts. Furthermore, their 
ability to modulate the immune system regulatory properties was investigated in ex vivo 
human Peripheral Blood Mononuclear Cells (hPBMCs) model, in collaboration with 
researcher of Universities of Camerino and Perugia. 
 
In the second paper the chemical characterization was further investigated focusing on 
HPLC quantification of KBA and βBA. Then, the primary culture of porcine aortic 
endothelial cells (pAECs) was chosen as an ideal in vitro model to study the anti-
inflammatory and angiogenic properties of two different formulations of B. serrata 
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Boswellia serrata (BS) is an important traditional medicinal plant that currently represents an interesting topic for pharmaceutical
research since it possesses several pharmacological properties (e.g., anti-inflammatory, antimicrobial, and antitumour). The safety
and versatility of this dietary supplement should allow for its use in numerous pathological conditions; however the quality of
the extracts needs to be standardized to increase the clinical success rate resulting from its use. In the present study, different
commercially available B. serrata extracts were employed to compare their AKBA content and in vitro antioxidant power.
Furthermore, their ability to modulate the immune system regulatory properties was investigated. Our results showed that the
AKBA content varied from 3.83 ± 0.10 to 0.03 ± 0.004%, with one sample in which it was not detectable. The highest antioxidant
power and phenolic content were shown by the same extract, which also exhibited the highest AKBA concentration. Finally, the
BS extracts showed the ability to influence the regulatory and effector T-cell compartments. Our results suggest that frankincense
should be further investigated for its promising potentiality to modulate not only inflammation/oxidative stress but also immune
dysregulation, but attention should be paid to the composition of the commercial extracts.
1. Introduction
The gum resin of Boswellia serrata (BS), a traditional treat-
ment of Ayurvedicmedicine in India also identified as Indian
frankincense, Salai Guggal, or Indian olibanum, has been
used for centuries as a remedy for many health problems [1].
Indeed, the anti-inflammatory, antiarthrogenic, and anal-
gesic activities of its dried resinous gum (guggulu), derived
from tapping the Boswellia tree, have been recognized since
ancient times [2]. The inflammatory response represents
the first-line defense of the body to tissue damage and/or
to microbial invasion and it determines the recruitment of
immune cells and some plasma proteins [3]. The final goal of
inflammation is healing, elimination of the external or inter-
nal inflammation noxae, and the restoration of homeostasis.
This immune response should be self-limiting but the
persistence of the stimulus in predisposed subjects leads to
chronification of the process and eventually to irreversible tis-
sue injury. Indeed, persisting low-grade inflammation plays
a key role in the pathogenesis of many chronic diseases [4]
and most of these diseases are also associated with increased
production of reactive oxygen species (ROS), which results in
oxidative stress [5]. Therefore, inflammation is tightly linked
with oxidative stress [6] by an interdependent relationship
and both participate in the pathogenesis of many chronic
diseases [4].
During recent decades, many authors have investigated
themechanisms of action of BS extracts related to the inflam-
matory process. Studies in animal models showed that the
ingestion of a defatted alcoholic extract ofBoswelliadecreased
polymorphonuclear leukocyte infiltration and migration as
well as primary antibody synthesis [7, 8] and led to almost
total inhibition of the classical complement pathway [9].
In vitro studies revealed that the boswellic acids, a group
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of pentacyclic triterpenoid compounds, and their acetylated
derivatives inhibit the biosynthesis of leukotrienes, the proin-
flammatory 5-lipoxygenase products which cause increased
permeability [10], in a dose dependent manner [11]. In addi-
tion, Cuaz-Pérolin et al. [12] observed that 3-acetyl-11-keto-
beta-boswellic acid (AKBA) was a natural inhibitor of the
transcription factor NFkB, whose presence is a prerequisite
for the formation/action of cytokines/chemokines involved
in inflammatory reactions.
Therefore, these natural compounds can dampen the
inflammatory response, but also simultaneously reduce
oxidative stress, as observed by Umar et al. [13].
In recent years, extracts from the gum resin of BS have
been shown to target both the humoral and adaptive immune
responses [14] eventually interfering with the inflammatory
cascade [15].
However, to the best of our knowledge, no studies have
yet investigated whether the BS extracts can exert any effects
on specific T-cell subsets whose balance is crucial for the
maintenance of immune homeostasis: the regulatory T-
cells (Tregs) and the proinflammatory Th1/Th17 cells. In
the present study, different commercially available B. serrata
extracts were employed as follows: (i) to compare their
composition and in vitro antioxidant power; (ii) to test their
ability to modulate Treg/Th1/Th17 cells ex vivo.
2. Materials and Methods
2.1. Chemicals and PlantMaterial. All chemicals used were of
analytical reagent grade from Sigma-Aldrich (St. Louis, MO,
USA). Six (A, B, C, D, E, and F, resp.) of the seven BS oleogum
resins utilized in the present study were commercially avail-
able and were certified for a content of boswellic acids of 65%.
The pale yellow or white amorphous powders were insoluble
in water but soluble in methanol and dimethyl sulfoxide
(DMSO). The seventh (G) BS extract was an aqueous extract
obtained by a process of bioliquefaction based on enzyme
biocatalysis [16] and was kindly offered by its producer
(Phenbiox, Calderara di Reno, Bologna, Italy).
2.2. TLC Analysis. BS extract separation was performed on
20 × 20 cm silica gel plates with a fluorescent indicator at
254 nm (Sigma-Aldrich, St. Louis, MO, USA). Pentane and
diethyl ether (2 : 1) containing 1% (v/v) of acetic acid were
used as a mobile phase. Twenty mg of BS extracts was
dissolved in 300 𝜇L of ethanol, sonicated for 5 minutes, and
centrifuged. Clear supernatant (10 𝜇L) was carefully layered
at 1.5 cm from the bottom of the plate giving an elution
distance of 9 cm. After the separation, plates were observed
at 254 nm and developed with anisaldehyde (5mL) in glacial




(1mL). The TLC analysis of
BSG extract was not performed due to its particular formula-
tion.
2.3. HPLC-DAD Analysis. A HPLC system (Beckman Coul-
ter, Brea, CA, USA), comprising a 116 pump, a 507 auto-
matic autosampler, an UV-Diode Array 168 detector, and
integration software 32 Karat, was used for the analysis
of seven BS extracts. Samples were prepared by dissolving
extracts in methanol. Briefly, the separation was performed
using a reverse phase column Luna C18 5𝜇m 250 × 4.6mm
(Phenomenex, Torrance, CA, USA) with a guard column
PR C-18 5 𝜇m 15 × 4.6mm (Phenomenex, Torrance, CA,
USA). Chromatographic separation was achieved in isocratic
conditions at room temperature. The mobile phase was





and acetonitrile (19 : 81 v/v). The flow rate was 1mL/min,
and the injection volume was 50 𝜇L. The analyses were
made at two different wavelengths (210 and 260 nm) and
UV spectra were recorded in the range of 190–300 nm. A
standard stock solution was prepared by dissolving 5mg
of AKBA analytical standard (Sigma-Aldrich, 5mg, batch
number BCBN2928V, CAS number 416619) in methanol
(5mL).The calibration curve was obtained by analyzing nine
serial dilutions (50 ppm, 25 ppm, 15 ppm, 10 ppm, 7.5 ppm,
5 ppm, 2.5 ppm, 1 ppm, and 0.5 ppm) of the stock solution
and by plotting the peak area measured at 260 nm against
AKBA concentrations. The following equation of the curve
was obtained:
𝑦 = 79739𝑥 − 5414, 𝑅2 = 0.999. (1)
The AKBA peaks were identified on the basis of the retention
time on the chromatogram at 260 nm. All measurements
were performed in triplicate and data were reported as mean
± SD.
2.4. Quantification of Total Phenolic Content (Folin-Ciocalteu
Method). The total content of polyphenolics was determined
by a colorimetric method as described by Singleton and
Rossi [17] and adapted to a 96-well plate format. Briefly, the
seven BS extracts were redissolved in 1mL of methanol and
100 𝜇L/well of each extract was dispensed into a flat bottom
96-well tissue culture plate (Becton Dickinson, Lincoln Park,
NJ); then 150𝜇L Folin-Ciocalteu reagent (1mL Folin-Denis’
reagent in 4mLH
2
O) was added.The plate was incubated for







O was added to each well and the plate was incubated for
a further 10min. The absorbance was measured at 765 nm.
A standard calibration curve was plotted using gallic acid
(0–300mg/L). The results were expressed as g of gallic acid
equivalents (GAE) per g of dry weight of BS extract. The
results were expressed as the average of three measurements.
2.5. Antioxidant Activity. Free radical scavenging activity
was studied using 1,1-diphenyl-2-picrylhydrazyl (DPPH) on
a microplate analytical assay according to the procedures
described by Srinivasan et al. [18], while the total radical
scavenging capacity of the same products was measured
by the 2,2-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) assay as modified by Re et al. [19], for application to
a 96-well microplate assay.
Finally, the determination of antioxidant activity by
FRAP assay was carried out according to the procedure
described by Müller et al. [20], monitoring the reduction of
Fe3+-tripyridyl triazine (TPTZ) to blue-colored Fe2+-TPTZ.
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Trolox was used as standard in all assays and the ability of
BS extracts to scavenge the different radicals was expressed
as tocopherol-equivalent antioxidant capacity (mmol TE/g
of product) and, for DPPH and ABTS assays, also as IC
50
,
the latter defined as the concentration of the tested material
required to cause a 50% decrease in initial DPPH/ABTS con-
centration. All measurements were performed in triplicate
and reported as mean ± standard deviation (SD).
2.6. Immune Responses
2.6.1. Cell Proliferation Assay. Human peripheral blood
mononuclear cells (PBMCs) of seven healthy donors (HD;
5 male and 2 female, age mean ± standard deviation: 47 ±
12.1 years) were isolated from fresh heparinized venous
blood (10mL/HD) by gradient separation. The study was
approved by the local ethics committee (CEAS Umbria)
and written informed consent was obtained from par-
ticipants in accordance with the Declaration of Helsinki.
The final concentration of live cells was adjusted to 1 ×
106/mL in complete medium (RPMI-1640 medium contain-
ing 10% heat-inactivated serum, L-glutamine (2mM), Euro-
clone, penicillin (100U/mL), and streptomycin (100 𝜇g/
mL), BiochromAG, Berlin). PBMCs were stained with car-
boxyfluorescein diacetate succinimidyl ester (CFSE) cell
tracer (BioLegend, San Diego, CA), dispensed into flat bot-
tom 24-well tissue culture plates (Becton Dickinson, Lincoln
Park, NJ) (1mL/well), and cultured for 5 days at 37∘C in
5% CO
2
. For proliferation stimuli were either 1 𝜇g/mL of
pokeweed mitogen (PWM; Sigma-Aldrich Co. Ltd., Saint
Louis, Missouri) or 1.2 𝜇g/mL of phytohemagglutinin (PHA;
BiochromAG, Berlin), in the presence or absence of two BS
extracts (0.1 𝜇g/mL). BS extractA revealed the highest in vitro
antioxidant power; BS extract Gwas obtained with a different
extraction method compared to other BS compounds (by
Phenbiox srl). So lymphocytes were exposed, in the cul-
ture medium, to an AKBA concentration of 3.8 ng/mL that
resulted below the mean maximal concentration of 6 ng/mL
detected in human plasma after an oral administration of a
BS dry extract in fasted condition [21].
A negative control was represented by PBMC cultured
without any mitogen/extract (C), so that the base prolif-
eration could be estimated [22]. Therefore, nine different
experimental theses for each blood sample were tested.
Flow cytometry analyses were performed on a standard
FACSCalibur flow cytometer (BectonDickinson,Mountain
View, CA) running the CellQuestPro software. The results
of the lymphocyte proliferation assay were expressed as a
percentage (%). Furthermore, the lymphocyte proliferation
index (LPI) was calculated with the following formula:
LPI = (FP − BV)
BV
∗ 100, (2)
where the FP values are represented by the “final percentages”
of cell proliferation (after 5 days in culture with BSs and
with/without the mitogens), whereas the BV values are
represented by the “basal values” obtained by cells either
stimulated (with PHA and PWM) or not (CTR) with the
mitogen but without BSs [23].
2.6.2. Phenotypic Characterization of Peripheral Blood Mono-
nuclear Cells. PBMCs obtained from the seven volunteers
were seeded further (1× 106 cells/well) into additional flat bot-
tom24-well tissue culture plates and cultured,with orwithout
PHA, for 5 days at 37∘C in 5% CO
2
. After culture, six-hour
in vitro stimulation with 25 ng/mL phorbol 12-myristate 13-
acetate (PMA), 1 𝜇g/mL ionomycin, and 1 𝜇L/mL BD Golgi-
Plug (BDBiosciences) in completemediumwas performed.
For surface staining, fluorescein isothiocyanate (FITC), Pe-
Cy7, or APC labelled antihuman CD4, CD3, and CD25 and
respective isotypes were used (BD Biosciences, San Jose, CA,
USA, Immunotools). Then, cells were permeabilised with
0.1% saponin blocking buffer after 4% paraformaldehyde fix-
ation to perform intracellular staining with Alexa Fluor 647
or Phycoerythrin (PE) antihuman IL-17 and INF𝛾, and their
isotype controls were used (BD Biosciences).When required,
cells were permeabilised with commercially available Fork-
head box protein P3 stain buffer (BD Biosciences) for
intracellular staining with PE-labelled mAb to human FoxP3
and respective isotype controls [24]. Debris was excluded
by backgating to CD3 T-cells in forward scatter/side scatter
(FSC/SSC) plots. Samples were analyzed using FACSCalibur
flow cytometer (BD) and CellQuestPro software (BD).
2.7. Statistical Analysis. The results of immune responses are
reported as mean ± standard error of the mean (SEM) from
seven samples of different HD. The unpaired Student’s 𝑡-test
was used to compare biological data from controls with that
from BS A or BS G treated samples, respectively (GraphPad
Prism, 2007) [25]. 𝑝 values < 0.05 for two-tailed test were
considered statistically significant.
3. Results
3.1. TLC Chromatograms. The preliminary qualitative TLC
screening of the BS extracts is shown in Figure 1. The UV
analysis revealed two main spots visible in all samples, with
the exception of extract C. The first spot had a Rf of 0.16,
whereas the second spot had a Rf of 0.29. The use of the
AKBA standard (lane S) allowed for the identification of this
boswellic acid in the spot with Rf of 0.29. It is noticeable that
extract C lacked the first spot and presented only traces of
the spot corresponding to AKBA, while extract A presented
the greatest spot referring to AKBA. Extracts A and E
presented other components absorbing at 254 nm. Figure 1(b)
demonstrates the pattern obtained after dyeingwith anisalde-
hyde, heating, and color development. Similar profiles were
obtained for extracts B, D, E, and F. Instead, extract E was
characterized by a major number of spots; extract A lost
the spots at the higher Rf; and extract C was found to have
fewer components. The majority of samples shared the spots
detected at Rfs of 0.24, 0.32, 0.40, 0.46, and 0.60.
3.2. HPLC-DADAnalysis. At 260 nm, themajority of extracts
presented twomajor peaks: the first one, at Rt of 13.2min, and













Figure 1: UVdetection at 254 nm (a) forUV-active boswellic acids. Chromatograms after dyeingwith anisaldehyde (b). Rf values are reported
for the most relevant spots. A–F: six different powder extracts of Boswellia serrata gum resin; S: 3-acetyl-11-keto-beta-boswellic-acid (AKBA)
analytical standard (Rf = 0.29).
Table 1: AKBA quantification in Boswellia serrata extracts. Data are
reported as mean ± SD (𝑛 = 3). Samples A–F = powder extracts,
sample G = hydroenzymatic extract.
Sample Concentration§ % in B. serrata extract#
A 38.30 ± 1.01 3.83 ± 0.10
B 17.18 ± 0.05 1.72 ± 0.005
C 3.08 ± 0.06 0.31 ± 0.01
D 24.35 ± 1.87 2.43 ± 0.19
E nd∗ nd
F 21.07 ± 0.16 2.11 ± 0.02
G 0.29 ± 0.04 0.03 ± 0.004
§AKBA concentration is expressed as mg/g of powder extract, with the
exception of sample G (mg/mL of hydroenzymatic extract); #AKBA percent-
age is expressed as g/100 g of powder extract, with the exception of sample G
(g/100mL of hydroenzymatic extract); ∗nd = not detectable.
the second one, identified as AKBA by the use of an analytical
standard, at Rt of 26min. Other minor peaks were also
present. AKBA concentrations for each sample, calculated on
the basis of the peak area and the calibration curve, are shown
in Table 1. Extract A presented significantly higher amounts
of AKBA as compared with the other samples. Extract C
presented only a small peak of AKBA andwas lacking the first
peak.
Other components in the BS extracts were visualized at
210 nm. The chromatograms of all the BS extracts analyzed
at the different wavelengths to highlight the variability of the
components present in the samples are reported in Figure 2.
3.3. Determination of Total Phenolic Content and Antioxidant
Capacity of Boswellia serrata Extracts. All the BS extracts
utilized in the present study exhibited a relatively low content
in phenolics ranging from 7.68±0.9mg gallic acid equivalent
(GAE)/g (extract A) to 0.11 ± 0.05mg GAE/g (aqueous
extract G) (Table 2). The chemical complexity of the extracts,
often mixtures of many compounds with differences in
functional groups, polarity, and chemical behavior, could
lead to scattered results, depending on the antioxidant test
employed. For these reasons, in the present study, the BS
extracts were screened for their free radical scavenging
and reducing properties through three test systems: (a) 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radical scavenging, (b)
monitoring of the reduction power of Fe3+ (FRAP assay), and
(c) evaluating the total radical scavenging capacity (ABTS
assay). All the BS extracts analyzed showed relative radical
scavenging activities in all the assays employed, revealing
antioxidant powers lower (from 34 to nearly 580 times) than
that of Trolox (positive control, Table 2).
However, between the BS extracts investigated, the BS
extract A showed the highest scavenging reducing power and
the highest polyphenolic content.
3.4. Immunomodulatory Activity. The in vitro lymphocyte
proliferation (CFSE assay) was not influenced by the BS
extracts if cells were cultured without any activator (data not
shown) or if stimulated by PHA. However, when cells were
activated by PWM, the addition of BS extracts induced a
significantly higher lymphocyte response (Figures 3(a) and
3(b)). No significant differences were observed between the
two types of BSs for the LPI (Figures 3(c) and 3(d)).
The in vitro regulatory or Th1/Th17 proinflammatory
responses (Figures 4(d), 4(e), and 4(f)) were not significantly
modulated by the addition of the BS extracts when PBMCs
were triggered by PHA. Neither type of utilized extract (A
versus G) elicited an altered response.
































































































































































































































Figure 2: Chromatograms of Boswellia serrata extracts (BS) after HPLC-DAD analysis. BS (A)–(F) extracts were diluted 1 : 400 in methanol,
whereas, BS (G) extract was diluted 1 : 20 in methanol. The chromatogram of the AKBA analytical standard is also reported (H). The
absorbance (mAU) is reported on the 𝑦-axis, wavelength (nm) on 𝑥-axis, and the retention time (minutes) on the 𝑧-axis.



















A 7.68 ± 0.9 31.8 ± 0.7 340.2 ± 3.5 151.8 ± 10.6 79.26 ± 1.8 66.89 ± 3.5
B 1.43 ± 0.5 4.48 ± 0.08 2416 ± 12.5 37.54 ± 2.5 320.30 ± 4.5 ND
C 0.56 ± 0.2 3.83 ± 0.08 2823 ± 27.5 1.92 ± 0.1 6250 ± 17.5 ND
D 1.09 ± 0.4 6.29 ± 0.12 1720 ± 13.8 27.8 ± 1.9 431.62 ± 6.5 ND
E 1.09 ± 0.3 5.41 ± 0.11 1998 ± 17.5 18.7 ± 1.2 641.75 ± 9.5 ND
F 0.96 ± 0.3 5.20 ± 0.15 2080 ± 22.5 20.6 ± 21.4 581.94 ± 8.5 ND
G 0.11 ± 0.05 1.85 ± 0.03 5820 ± 32.5 1.76 ± 0.1 6800 ± 22.5 ND
Positive control
Trolox 10.85 ± 0.2 3.01 ± 0.2
aTEAC = Trolox equivalent (TE) antioxidant concentration. bIC50 =The concentration of compound that affords a 50% reduction in the assay; GAE = gallic
acid equivalent. ND = not detectable.







































p = 0.03 p = 0.02
A
B B


























Figure 3: Boswellia serrata (BS) extract (A or G) effects on lymphocyte proliferation assay. Data are shown as mean ± SEM of seven
independent experiments. PBMCs were cultured with phytohemagglutinin (PHA; graphics (a) and (c)) or pokeweed mitogens (PWM;
graphics (b) and (d)) and stained with carboxyfluorescein diacetate succinimidyl ester cell tracer (CFSE).The lymphocyte proliferation index
(LPI) was calculated as reported in the text. A,BDifferent letters for 𝑝 < 0.05. n.s. = not significant.
However, when cells were not PHA pulsed, an increase of
FOXP3+ cells was observed in PBMCs cultured with the BS
extracts. In particular, a tendency towards a higher number
of regulatory cells was observed for extract A (𝑝 = 0.079),
whereas extract G led to a significant increase of FOXP3+ cells
(𝑝 = 0.045; Figure 4(a)).
Furthermore, higher number ofTh17+ cells, although not
significant, was again observed when PBMCs were cultured
with the extract G (Figure 2(C)).
4. Discussion
The therapeutical efficacy of BS extracts has been extensively
investigated in arthritis, asthma, diabetes mellitus, colitis,
and cancer [26, 27] in light of their antioxidant and anti-
inflammatory activities [28]. Indeed, all these diseases share
a persistent dysregulation of redox status that contributes
to the intensity and duration of the inflammatory response
and therefore to the induction and perpetuation of chronic
inflammation.
It is noteworthy that the phytochemical content of B.
serrata oleogum resin is dependent on both the botanical
origin and the geographical origin [29]. Usually it consists
of 30–60% triterpenes (such as 𝛼- and 𝛽-boswellic acids,
lupeolic acid), 5–10% essential oils, and 20–35% polysaccha-
rides [30]. According to Singh et al. [31], in aqueous and
ethanolic extracts of B. serrata, it is possible to recognize
alkaloids, carbohydrates, phytosterols, terpenoids, phenolic
compounds, flavonoids, and tannins. However, other authors
found also glycosides, proteins, and saponins [32].
Furthermore, the wide variations of pharmacologically
active molecules in commercial BS formulations could sig-
nificantly affect the final product [33].
The first aim of this study was to perform a comparative
analysis on the composition of different dry and aqueous
extracts of B. serrata gum resin as a tool for the evaluation
of the quality of the extracts.
Combination of TLC and HPLC analyses can be con-
sidered as a multidimensional analytical approach combin-
ing fast qualitative screening with an accurate and precise
quantification of specific compounds.We decided to quantify
AKBA because the boswellic acid, characteristic and unique
to Boswellia genus, is considered the most effective, at least
in in vitro studies. When analyzed at 260 nm, four of the
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Figure 4: Boswellia serrata (BS) extract (A or G) effects on Treg (CD4+CD25+FOXP3+ cells),Th1 lymphocyte (INF𝛾+ cells), andTh17 cell (IL-
17+) responses. Data are shown as mean ± SEM of seven independent experiments. PBMCs were cultured in absence (controls, C; graphics
(a), (b), and (c)) or presence of mitogen (phytohemagglutinin, PHA; graphics (d), (e), and (f)) and with/without BS extracts. A,BDifferent
letters for 𝑝 < 0.05. n.s. = not significant.
seven samples presented comparable profiles, characterized
by the presence of two main peaks the second of which
corresponds to AKBA.The other components of BS extracts,
lacking the keto moiety, were visualized only at a less specific
wavelength (210 nm) as already reported [34]. The AKBA
concentrations detected in samples A, B, D, and F are similar
to those reported by other authors [30, 35], while those found
in extracts C and G were 10 or 100 times lower, respectively.
It can be hypothesized that extract C belongs to Boswellia
species other than B. serrata, due to a wrong botanical
identification by local producers. Indeed, it has already been
reported that the elution profile of Boswellia frereana gum
resin lacks KBA and AKBA peaks [34], while Boswellia sacra
gum resin contains much lower amounts of KBA and less
AKBA than B. serrata [34, 36]. Concerning extract G, this
aqueous extract showed a lower content of AKBA, but it
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was enriched by other components of the phytocomplex,
as demonstrated by the additional peaks obtained in the
elution profile at 210 nm.The presence of these compounds is
probably related to the particular and innovative extraction
method [16].
The composition of BS extract E is challenging, due to the
discrepant results in TLC and HPLC analysis. The spot at Rf
of 0.26, a putative AKBA component, was not confirmed by a
corresponding peak in the HPLC chromatogram at 260 nm.
Other components of the phytocomplexes containing a keto
moiety should have contributed to this spot and further
analyses are needed to identify these molecules.
The antioxidative potential and radical scavenging activ-
ity of aqueous and ethanolic extracts of B. serrata are
significantly correlated to their total phenolic and flavonoid
content [31].
According to Kohoude et al. [37], the amount of phe-
nolics in Boswellia genus (315 g/kg) is comparable to ref-
erence extracts rich in phenolic compounds. Despite what
is reported in literature, the BS samples investigated here
were all characterized by either relatively low antioxidant
properties or total phenolic content. Indeed, the latter ranged
from 0.11 ± 0.05 to 7.68 ± 0.9mg GAE/g versus values of
28.46–12.73mg GAE/g obtained by other authors in aqueous
and ethanolic extracts, respectively [31].
According to the extraction procedure, the antioxidant
activity increased with the polarity of the solvent. Other
authors reported that the essential oil ofBoswellia dalzieliiwas
characterized by low antioxidant activity [36] and that this
was due to the extraction method adopted (e.g., low polarity
of the solvent) that determined the absence of phenolics,
especially flavonoids.
In the present study, the extraction methods adopted
by manufacturers or even the preservative systems used
could be responsible for the low level of total phenolic and
flavonoids compounds, which are contained mainly in the
volatile essential oil component of the oleogum resin.
Furthermore, although theoretically the aqueous extract
(extract G) should have characteristics closest to the natural
product being obtained by an enzymatic hydrolysis that
maintains the intact phytocomplexes [16], we observed that it
was the one with the lowest antioxidant properties and total
phenolic contents.
However, these results are at least partially in line with
those of other authors reporting that the wild habitat samples,
with a completely different profile as compared to the market
samples, were those lacking antioxidant activity [28].
Nevertheless, the BS extracts of the present study were
able to significantlymodulate some immune responses inves-
tigated independently of the in vitro antioxidant activities. As
reported in Figure 3(b), when cells were stimulated by PWM,
a mitogen that stimulates B lymphocytes in the presence of
T-cells, the PBMC proliferation was significantly increased
(𝑝 < 0.05) by the addition of the BS extracts (0.1 𝜇g/mL for
both extracts A and G) and the LPI did not change between
the two BS extracts (Figure 3(d)).
Conversely, when cells were activated by PHA, neither
the PBMC proliferation (mainly, T-cells+) nor the LPI were
affected by the BS extracts (Figures 3(a) and 3(c)).
It has been previously reported that the BS could produce
opposing effects on immune responses in vivo or in vitro.
Potentially low concentrations of BSs increase stimulated
proliferation of lymphocytes whereas higher concentrations
are even inhibitory [14].
Sharma et al. [38] reported that a mixture of various
boswellic acids in the range of 1.95–125 𝜇g/mL inhibited mice
splenocytes stimulated with lipopolysaccharides (LPS), PHA,
alloantigen, and concanavalin A (ConA), in a concentration-
dependentmanner. Indeed, a significant inhibition of spleno-
cytes to mitogens and alloantigens was observed starting
from concentrations greater than 3.90 𝜇g/mL.
On the other hand, Gayathri et al. [15] observed that
30 𝜇g/mL of a crude methanolic BS extract is able to inhibit
almost 80% of human lymphocyte proliferation. These data
are in striking contrast with the observations of other authors
[39] who tested the effect of 1mg/mL of BS total alcoholic
extract, gum, or volatile oil on human lymphocyte prolifera-
tion and observed no inhibition of cells stimulatedwith either
PHA or Con A.
Besides the different lymphocyte proliferation assays
applied, the BS concentrations used in the present study were
10 to 1000 times lower than those adopted in the cited articles
and, at these doses, we obtained an effect on the lymphocyte
proliferation only when cells were stimulated by PWM (B
cells+).
However, in mice treated with orally administered
boswellic acids, the secondary antibody titres were appre-
ciably enhanced at the lowest tested doses (25mg/kg body
weight versus 100–200mg/kg) [38].
The dose of BS extracts we adopted was probably low
enough to induce an effect on B cells+ (activated by PWM),
but too low to induce an inhibition of T lymphocyte prolifer-
ation, as reported by other authors [14, 39].
In the maintenance of T-cell balance a pivotal role is
attributed to T-helper cells and regulatory T-cells [40, 41]. T-
helper cells are defined as Th1-, Th2-, or Th17-cells and are
characterized by differential expression of certain cytokines
[42]. Th1-cells have the capacity to express the key cytokine
interferon-𝛾 (IFN-𝛾), whereas Th17-cells, a more recently
described T-helper cell subset, evolutionally and functionally
divergent fromTh1 andTh2 cell subsets, are characterized by
their ability to produce interleukin-17A (IL-17A) [43].
Regulatory T-cells (Tregs) suppress effector T-cells and,
in humans, can be characterized by a CD4+CD25highFoxP3+
phenotype [41].
In our study, we observed that when PBMCs from
healthy controls were not activated by PHA mitogen, the
presence of BS extract G in the culture medium determined
a significant increase of Tregs (Figure 4(a)). Furthermore, the
increased number of Treg cells in BS G treated samples was
accompanied by a higher number, although not significant,
of Th17+ cells. Conversely, the BS extracts did not influence
the number ofTh1+ cells (INF𝛾+). When PBMCs were pulsed
by PHA, no additional effect could be seen following the BS
extract addition.
The recent evidence of a developmental plasticity between
Treg andTh17 cells prompts the investigation of intermediate
phenotypes that result from their reciprocal conversion
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according to the surrounding microenvironment [44]. The
presented results show a possible role for BS extracts in such
a fine balance between these two cell subsets.
Furthermore, it is important to note that, at least in mice,
Th17 lymphocytes can also function as B-cell helpers [45],
mediating B-cell differentiation and antibody class switch
recombination. The results of our lymphocyte proliferation
assay showed that the BS extracts exerted a significant
stimulatory effect on B+ cell proliferation, possibly mediated
by an enhanced number of Th17+ cells.
Many authors have demonstrated that B. serrata extracts
turn out to be effective in the treatment of diseases such
as inflammatory bowel disease and osteoarthritis in which
inflammation and/or oxidative stress exert an important
pathogenic role [2, 13, 30, 46].
However, BS extracts also exerted beneficial effects in
some autoimmune diseases, such as rheumatoid arthritis [1],
where chronic inflammation and an aberrant autoimmune
response are hallmarks of the disease [47].
This ex vivo study provides evidence that B. serrata
extracts, besides their reported capacity in dampening the
inflammatory response together with counteracting the
oxidative stress, were able to influence the regulatory and
effector T-cell compartments.
In order to draw conclusions, it will be necessary to
deepen the experiment on a wider case study. However,
these preliminary results suggest that frankincense should
be further investigated for its promising ability to inter-
fere, possibly also through such regulatory mechanism, on
immune dysregulation typical of various immune disorders,
but attention should be paid to the quality of the commercial
extracts which can show wide variations in their chemical
composition.
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This study is aimed at investigating the cytotoxicity, anti-inflammatory, and angiogenic activities of two Boswellia serrata extracts
on primary culture of porcine aortic endothelial cells (pAECs). Chemical characterization of a dry extract (extract A) and a
hydroenzymatic extract (extract G) of B. serrata was performed by HPLC using pure boswellic acids (BAs) as standard. In
cultured pAECs, extract G improved cell viability, following LPS challenge, in a dose-dependent manner and did not show any
toxic effect. On the other hand, extract A was toxic at higher doses and restored pAEC viability after LPS challenge only at lower
doses. Pure BAs, used at the same concentrations as those determined in the phytoextracts, did not contrast LPS-induced
cytotoxicity. Extract A showed proangiogenic properties at the lowest dose, and the same result was observed using pure AKBA
at the corresponding concentration, whereas extract G did not show any effect on the migration capacity of endothelial cells. In
conclusion, an anti-inflammatory activity of B. serrata extracts on endothelial cells was reported, though cytotoxicity or
proliferative stimulation can occur instead of a protective effect, depending on the dose and the formulation.
1. Introduction
The endothelium, uniquely positioned at the interface
between the vascular wall and the blood, regulates multiple
functions such as maintenance of normal vascular tone,
modulation of coagulation, and immune responses [1]. It is
widely demonstrated that the exposure of endothelial cells
to proinflammatory stressors results in the production of
molecules correlated with a proadhesive, prothrombotic,
and proinflammatory phenotype that contributes to vascular
disorders [2, 3], including cardiovascular diseases (CVDs).
Since ancient times, the extracts from the oleo-gum resin
of Boswellia serrata Roxb. ex Colebr. (family Burseraceae),
also identified as Indian frankincense or Salai Guggal, have
been used in traditional Ayurvedic medicine for the treat-
ment of inflammatory diseases, including osteoarthritis and
chronic bowel diseases [4–8].
The oleo-gum resin, obtained by incision of the bark,
is composed by essential oil (5–9%), mucopolysaccarides
(21–22%), and pure resin (65–85%), containing tetracyclic
and pentacyclic triterpene acids, of which boswellic acids
(BAs) are the most important bioactive molecules [4, 9, 10].
In particular, 11-keto-β-boswellic acid (KBA) and 3-O-ace-
tyl-11-keto-β-boswellic acid (AKBA) were proposed to act
as inhibitors of 5-lipoxygenase (5-LO) [11, 12]. Recently,
other components of the phytocomplex, such as β-boswel-
lic acid (βBA), have been suggested as anti-inflammatory
molecules, acting through inhibition of serine protease
cathepsin G (catG) and microsomal prostaglandin E syn-
thase (mPGES) [9].
Differences in the relative amount of BAs and other com-
ponents of the phytocomplex are related to the existence of
different species of the genus Boswellia, to environmental
conditions (e.g., soil composition, season, and air humidity),
and to the extraction procedure [13] leading to herbal prod-
ucts of different composition and quality. In a previous study,
seven B. serrata extracts were compared for their AKBA con-
tent and antioxidant power, highlighting wide variations
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[14]. In particular, one of the extracts obtained by biolique-
faction based on enzyme biocatalysis (hydroenzymatic
extract) [15] showed interesting peculiarities. A lower con-
tent of AKBA and antioxidant power but higher activity in
ex vivo tests on peripheral blood mononuclear cells (PBMCs)
was determined in comparison with the dry extract [14]. In
recent years, attention has also been focused on the role of
other BAs, namely, KBA and βBA [16, 17], suggesting a pos-
sible pharmacological activity also for these BAs. Preliminary
data showed wide variability in the concentration of BAs in
different extracts [18]; therefore, the present research is
aimed at deepening the chemical characterization of the
two extracts previously studied, focusing on HPLC quantifi-
cation of KBA and βBA. The effect of different formulations
will be evaluated in comparison with the individual pure BAs
in an interesting in vitro model: primary culture of porcine
aortic endothelial cells (pAECs). With pig as an excellent
model for translational medicine in the cardiovascular field
[19, 20], we have previously isolated and cultured endothelial
cells from thoracic aortas [21]. These primary cultures main-
tain a stable phenotype, and they prove to be an excellent
model of study for the vascular response to different stressors
[22, 23]. Therefore, pAECs were chosen as an ideal in vitro
model to study the anti-inflammatory and angiogenic prop-
erties of the two B. serrata extracts in comparison with pure
AKBA, KBA, and βBA, either individually or mixed together.
2. Materials and Methods
2.1. Chemicals and Reagents. Human endothelial SFM
medium, heat-inactivated fetal bovine serum (FBS), antibi-
otic-antimycotic, and Dulbecco’s phosphate-buffered saline
(DPBS) were purchased fromGibco-Life technologies (Carls-
bad CA, USA). Dimethyl sulfoxide (DMSO), trypsin EDTA
solution, lipopolysaccharide (LPS) (E. coli 055: B5), glycerol,
methanol, phosphoric acid, acetonitrile, and AKBA (batch
number BCBN2928V and CAS number 67416-61-9) were
purchased from Sigma-Aldrich Co. (St Louis, MO, USA).
KBA and βBA (batch numbers 15020106 and 15010405
and CAS numbers 17019-92-0 and 631-69-6, resp.) were
obtained from PhytoPlan (Heidelberg, Germany). Six out of
seven samples (extracts A–F) are dry extracts of B. serrata
oleo-gum resin. The powder is insoluble in water but soluble
in methanol and dimethyl sulfoxide (DMSO). Extract G is an
aqueous extract obtained by a process of bioliquefaction
based on enzyme biocatalysis [15]. Briefly, the gum resin
from B. serrata was suspended in water (1 : 10 w/v) and sub-
jected to enzymatic digestion by xylanase, α-amylase, and
glucosidase for 24hours. One ml of hydroenzymatic extract
is obtained from 145mg of B. serrata resin (145mg resin/ml).
2.2. Qualitative and Quantitative Characterization of B.
serrata Extracts. Qualitative and quantitative analyses of B.
serrata extracts were performed by a reversed-phase high-
performance liquid chromatography (HPLC) method using
the HPLC system (Beckman Coulter, Brea, CA, USA), com-
prising a 116 pump, a 507 automatic autosampler, a UV-
Diode Array 168 detector, and integration software 32 Karat
as reported by Beghelli et al. [14]. Seven samples (A–G) were
analyzed for KBA and βBA concentrations and were pre-
pared by dissolving extracts in methanol. KBA and βBA stan-
dard stock solutions were prepared by dissolving 5mg of
analytical standard in methanol (5mL). The calibration
curves were obtained by analyzing six serial dilutions
(50 ppm, 25ppm, 10 ppm, 5 ppm, 2.5 ppm, and 1 ppm) of
the stock solution and by plotting the peak area measured
at 260nm against KBA concentrations and at 210 nm against
βBA concentrations. The following equations of the curves
were obtained:
KBA = 77361x + 44918, r2 = 0 999,
βBA = 26532x + 721 54, r2 = 0 999
1
The KBA and βBA peaks in the samples were identified
on the basis of the retention time on the chromatogram
at 260nm and 210 nm, respectively. All measurements
were performed in triplicate and data were reported as
mean ± SD.
2.3. Cell Culture and Treatment. Porcine aortic endothelial
cells (pAECs) were isolated and maintained as previously
described by Bernardini et al. [21]. All experiments were per-
formed with cells from the third to the eighth passage. The
first seeding after thawing was always performed in T-25 tis-
sue culture flasks (3× 105 cells/flask) (T-25, BD Falcon,
Franklin Lakes, NJ, USA), and successive experiments were
conducted in 24-well plates (scratch test) or 96-well plates
(cell viability) with confluent cultures. Cells were cultured
in human endothelial SFM medium, added with FBS (5%)
and antimicrobial/antimycotic solution (1x) in a 5% CO2
atmosphere at 38.5°C. Extract A was dissolved in DMSO at
10mg dry extract/ml (stock solution) and then diluted in cul-
ture medium to obtain four doses containing 0.1, 1, 10, and
100μg of dry extract/ml, respectively. Extract G, which is
an aqueous solution, was directly diluted in culture medium
to obtain four doses referring to 2.4, 24, 240, and 2400μg of
resin/ml. These doses were chosen and normalized on the
basis of AKBA concentration in extracts as reported in [14]:
for both extracts, the lowest dose contained 3.8 ng/ml of
AKBA and the highest dose contained 3.8μg/ml of AKBA.
Pure analytical grade BAs (KBA, AKBA, and βBA) were
dissolved in methanol (stock solution 1mg/ml) and then in
culture medium to obtain the required concentrations. Two
doses were chosen: low, corresponding to 3.8 ng/ml AKBA,
3 ng/ml KBA, and 8ng/ml βBA, and high, corresponding to
380 ng/ml AKBA, 300 ng/ml KBA, and 800ng/ml βBA. For
each treatment, the same concentration of the specific vehicle
was used as control.
2.4. Effect of B. serrata Extracts on pAEC Viability. pAECs
were seeded in a 96-well plate (6× 103 cells/well) and exposed
to four increasing doses of B. serrata extracts for 24h. Cell
viability was measured using tetrazolium salt (MTT assay).
The formazan absorbance was measured at a wavelength of
570 nm, using Infinite® F50/Robotic absorbance microplate
readers from TECAN (Life Sciences). The background absor-
bance of multiwell plates at 690nm was also measured and
subtracted from the 570nm measurements.
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2.5. Effect of B. serrata Extracts on LPS-Induced pAEC Death.
pAECs seeded in a 96-well plate (6× 103 cells/cm2) were
exposed to lipopolysaccharide (LPS) (25μg/ml) for 24 h
either in the presence or in the absence of extracts A and G
or pure BAs at the concentrations reported above. Cell viabil-
ity was evaluated by MTT assay.
2.6. Effect of B. serrata Extracts on pAEC Migration Capacity.
pAECs were seeded in a 24-well plate (4× 104 cells/well).
When cells reached confluence, a wound was induced
scratching the surface by a pipette tip, then the detached
cells were removed by washing with DPBS. Complete
medium containing low and high doses of extract A (0.1μg
dry extract/ml and 10μg dry extract/ml) and extract G
(2.4μg resin/ml and 240μg resin/ml) and pure BAs at low
(3 ng/ml KBA, 3.8 ng/ml AKBA, and 8ng/ml βBA) and high
(300 ng/ml KBA, 380ng/ml AKBA, and 800ng/ml βBA)
concentrations were added. Microscopic phase-contrast
pictures and three measurements of the damaged areas
were taken immediately after the scratches (T0) and after
6 h (T1) and 24 h (T2). Images were acquired using a Nikon
epifluorescence microscope equipped with digital camera
(Nikon, Yokohama, Japan).
2.7. Statistical Analysis. Each treatment was replicated three
times (migration capacity) or eight times (cell viability and
LPS challenge). Data were analyzed with a one-way analysis
of variance (ANOVA) followed by the Tukey post hoc com-
parison test or Student’s t-test. Differences of at least p < 0 05
were considered significant. Statistical analysis was carried
out using R software (http://www.R-project.org).
3. Results
3.1. KBA and βBA Quantification by HPLC-DAD Analysis.
Representative chromatograms of KBA, AKBA, and βBA
analytical standards as well as extracts A and G analyzed at
210 and 260nm are reported in Figure 1.
Both extracts presented two major peaks at 260nm: the
first one, at Rt of 13.2min, identified as KBA by the use of
the analytical standard, and the second one, at Rt of 26min,
previously identified as AKBA. Other components of the B.
serrata phytocomplex were only visualized at 210nm, and
the peak at Rt of 49min was identified as βBA by the use of
the analytical standard. KBA, AKBA, and βBA concentra-
tions, calculated based on the peak area and the calibration
curve, are shown in Table 1.
Quantitative and qualitative differences were present.
The concentrations of BAs in extract G were two orders of
magnitude lower than in extract A, and the chromatogram
of extract G was characterized by a major number of peaks
resolved at 210nm. Data on KBA and βBA concentrations
in other additional five dry extracts (B–F) are reported in
Table S1 in the Supplementary Material.
3.2. Effect of B. serrata Extracts on pAEC Viability. Extract A
was cytotoxic at higher concentrations, resulting in a
reduction in cell viability of 12 and 47%, respectively,
while lower concentrations did not affect cell viability
(Figure 2(a)). Extract G did not show any toxic effect on
pAECs (Figure 2(b)). In the presence of pure BAs, a sig-
nificant (p < 0 05) cytotoxic effect was detected at the con-
centrations studied (Figure 2(c)). Only AKBA presented a
dose-dependent effect.
3.3. Effect of B. serrata Extracts on LPS-Induced pAEC Death.
LPS challenge determined a significant 30% reduction of cell
viability. Extract A significantly (p < 0 05) reduced the cyto-
toxicity induced by LPS at the lower concentrations
(Figure 3(a)). The highest concentration elicited a significant
exacerbation of LPS cytotoxicity resulting in 70% reduction
of cell viability, while the lowest concentration showed a sig-
nificant proliferative effect, resulting in a 40% increase in cell
viability. Extract G significantly (p < 0 05) restored pAEC
viability after LPS treatment at all the concentrations ana-
lyzed (Figure 3(b)), without a dose-dependent effect. None
of pure BAs, individually or mixed together, was able to
contrast LPS cytotoxicity (Figure 3(c)).
3.4. Effect of B. serrata Extracts on pAEC Migration Capacity.
Extract A reduced the damaged area at T1 (6 h) and restored
completely the monolayer at T2 (24 h) at the lower concen-
tration, while at 10μg dry extract/ml no significant effect
on cell proliferation was measured (Figure 4(a)). The incuba-
tion with extract G did not determine the recovery of the
damage (Figure 4(b)). Pure BAs showed a significant
wound-healing effect at the end of the incubation at the lower
concentration (Figure 4(c)). In particular, AKBA at 3.8 ng/ml
completely restored the monolayer.
4. Discussion
The gum resin obtained from B. serrata, used in Ayurvedic
medicine for the treatment of a variety of diseases, is consid-
ered a promising natural source of anti-inflammatory mole-
cules, in particular BAs [4, 9].
The quantification of these active molecules is a prerequi-
site for testing any biological effect of a phytoextract from B.
serrata. Therefore, the first aim of this study was to better
characterize the BA profile through the quantification of
KBA and βBA in addition to AKBA. The concentrations of
BAs determined in extract A are in the range of those
reported by other authors [24–26]. AKBA and KBA are used
as markers to ensure the quality of B. serrata dry extracts, but
their concentrations show wide variability in commercial
products, which in general claim 65% of BAs. In general,
BAs represent only a percentage of total organic acids,
whose concentrations are determined by unspecific titra-
tion methods and, as a consequence, the claimed content
of 65% BAs is absolutely unrealistic as recently pointed
out also by other authors [24, 25]. Very low percentages
of KBA and βBA were found in extract G compared to
extract A. This aqueous extract was also characterized by
low AKBA and low polyphenol concentrations [14], con-
firming again the importance of the extraction procedure
on the phytocomplex composition.
To evaluate the possible biological effects of these differ-
ent formulations, extracts A and G, normalized on the basis
of AKBA content, were used for in vitro analyses to assess
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cytotoxicity, anti-inflammatory activity, and angiogenic
properties in comparison with pure BAs. Cytotoxic effects
of B. serrata dry extracts and BAs were reported in sev-
eral studies in different cancer cell lines, such as leukemia
cells, prostate cancer cells, and gastrointestinal cancer
cells [7, 27–30]. As regards the biochemical mechanism
of cell death, Liu et al. [31] reported that BAs are able
to induce apoptosis in Hep-G2 cells through the activa-
tion of caspase-8, while Bhushan et al. [32] found that
a triterpendiol derived from BAs induced apoptosis in
HL-60 cells through the activation of Bcl-2 and caspase-3.
The anti-inflammatory activity of Boswellia extracts was
demonstrated in microvascular endothelial cells by prevent-
ing TNFα-induced expression and activity of MMP-3,
MMP-10, and MMP-12 [33]. Moreover, previous studies
have shown that B. serrata extracts and BAs antagonize the
inflammatory effect of LPS in human and mouse macro-
phages, monocytes, and PBMCs [34–36]. Our results demon-
strated for the first time the protective effect of B. serrata
extracts against LPS inflammatory stimulus in endothelial
cells. In particular, extract G was the most effective,
restoring completely cell viability at all the doses studied
without any cytotoxicity. On the contrary, increasing





















































































Figure 1: Representative chromatograms of pure analytical grade BAs (KBA, AKBA, and βBA) (25 ppm each) (a), extract A (b), and extract G
(c) at 210 (pink chromatogram) and 260 nm (black chromatogram).
Table 1: KBA, βBA, and AKBA quantification in Boswellia serrata
extracts. Data are reported as mean ± SD (n = 3). Concentration is
expressed in mg/g of dry extract (extract A) or mg/ml of
hydroenzymatic extract (extract G). For each BA, significant
differences between extracts are indicated by ∗(p < 0 05, Student’s
t-test) and by ∗∗(p < 0 001, Student’s t-test).
Extract KBA§ βBA AKBA§
A 15.86± 0.56∗∗ 33.53± 7.23∗ 38.30± 1.01∗∗
G 0.19± 0.02 0.50± 0.03 0.29± 0.04
§Data of AKBA concentrations are reported in Beghelli et al. [14].
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Figure 2: Effect of increasing doses of B. serrata extract A (0.1, 1, 10, and 100μg dry extract/ml) (a), extract G (2.4, 24, 240, and 2400 μg
resin/ml) (b), and pure BAs (low, corresponding to 3.8 ng/ml AKBA, 3 ng/ml KBA, and 8 ng/ml βBA, and high, corresponding to 380 ng/ml
AKBA, 300 ng/ml KBA, and 800 ng/ml βBA) (c) on pAECs. Cell viability was measured by MTT assay. Data are reported as mean ± SD
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Figure 3: Effect of increasing doses of B. serrata extract A (0.1, 1, 10, and 100μg dry extract/ml) (a), extract G (2.4, 24, 240, and 2400 μg
resin/ml) (b), and pure BAs (low, corresponding to 3.8 ng/ml AKBA, 3 ng/ml KBA, and 8 ng/ml βBA, and high, corresponding to
380 ng/ml AKBA, 300 ng/ml KBA, and 800 ng/ml βBA) (c) on pAEC viability, in the presence of LPS (25 μg/ml), measured by MTT assay.
Data are reported as mean ± SD of 8 independent replicates. Different letters above the bars indicate significant differences (p < 0 05
ANOVA post hoc Tukey’s test).










































































































Figure 4: Effect of B. serrata extracts on pAEC migration capacity. Cells were scratch wounded and then treated with extracts A and G and
pure BAs. Photographs were recorded at 0 h (T0), 6 h (T1), and 24 h (T2) after scratching. (a) Representative microscopic phase-contrast
pictures showing the size of the scratch wound in different treatment groups compared with control. Scale bar, 200μm. The extent of the
damaged area (%) is reported for treatment with extract A (0.1 and 10 μg dry extract/ml) (b), extract G (2.4 and 240μg resin/ml) (c), and
pure BAs (low, corresponding to 3 ng/ml KBA, 3.8 ng/ml AKBA, and 8 ng/ml βBA, and high, corresponding to 300 ng/ml KBA, 380 ng/ml
AKBA, and 800 ng/ml βBA) (d). Data are reported as mean of 3 replicates ± SD. Inside each experimental time (T1 and T2), different
letters above the bars indicate significant differences among treatments (p < 0 05, ANOVA post hoc Tukey’s test).
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from hyperproliferative effect (the lowest dose) to cytotoxic
effect (the highest dose). Interestingly, in our model the use
of pure KBA, βBA, and AKBA, either individually or mixed
together, failed to protect endothelial cells from LPS
toxicity and are only partially in accord with data reported
by Henkel et al. [35]. In a cell-free assay, those authors
suggested a direct molecular interaction between LPS and
BAs lacking the keto moiety, in particular βBA, underlying
the anti-inflammatory effect of Boswellia extracts.
Our results support the hypothesis that the anti-
inflammatory effect of Boswellia extracts is not strictly
dependent on the presence of the most studied BAs, but
it can be related to other bioactive molecules. Other triter-
penes, as incensole, could be considered interesting candi-
dates for the pharmacological properties of frankincense,
accordingly to suggestions previously reported by other
authors [9, 37, 38]. Beyond these bioactive terpenes, the
gum resin does contain polysaccharides. These molecules
are likely to be minor components in dry extract A, whereas
they can be more concentrated in extract G, due to the
different polarity of the extraction medium. A water-soluble
fraction extracted from the gum resin of B. serrata
containing galactose, arabinose, and D-glucuronic acid was
suggested to act as a potent enhancer of humoral and cell-
mediated immune response [39], while the potential anti-
inflammatory activity of these polysaccharides has not yet
been explored. We cannot exclude that the polysaccharide
fraction present in extract G can develop additional
modulatory effects on pAECs.
The migration ability of endothelial cells is critical in the
physiological and pathological angiogenesis [40]. Our results
obtained with an in vitromodel of physiological angiogenesis
showed proangiogenic activity of extract A at the lowest con-
centration, in agreement with a proliferative effect of the
same dose recorded in LPS challenge. In addition, incubation
with pure AKBA at the same concentration as that measured
in extract A determined the same proangiogenic effect, indi-
cating a possible involvement of this BA in promoting angio-
genesis. In contrast, incubation in the presence of extract G
containing the same concentrations of AKBA did not show
any effect on endothelial cell migration capacity, indicating
one more time the existence of complex molecular interac-
tions, which can modify the biological effect of the phytoex-
tract. Contrasting results are also reported in literature.
Lulli et al. [41] observed that AKBA reduced proliferation,
migration, and tube formation in human retinal microvascu-
lar endothelial cells (HRMECs) stimulated with exogenous
vascular endothelial growth factor (VEGF). On the other
hand, Wang et al. [17] reported that β-BA can attenuate
endothelial cell injury in a blood stasis model and protect
human umbilical vein endothelial cells (HUEVCs) against
cell death induced by oxygen and glucose deprivation. Differ-
ent regulation pathways could be involved in the repairing
activity of Boswellia extracts, and further investigations will
be necessary to explain why different formulations determine
different effects on endothelial cells pathophysiology.
How extracts of B. serrata gum resin should modulate
the cardiovascular system has been scarcely investigated,
so far. Kokkiripati et al. [42] reported that antioxidant
and antithrombotic activities of extracts from B. serrata
gum resin determined the inhibition of human monocytic
cell activation and platelet aggregation. However, recently
Siemoneit et al. [43] pointed out the complex agonizing
and antagonizing effects of BAs on human platelet aggre-
gation and prompted for careful evaluation of B. serrata
extract safety in cardiovascular disease-risk patients.
In conclusion, our results demonstrate that different
formulations (e.g., dry and hydroenzymatic extracts)
obtained from the same botanical species show significantly
different biological effects on endothelial cells. The anti-
inflammatory activity of B. serrata extracts on endothelial
cells suggests a potential pharmaceutical application for
cardiovascular health, though cytotoxicity or proliferative
stimulation can occur instead of a protective effect, depend-
ing on the dose and the formulation. This aspect should be
carefully considered when these herbal products are used in
human and animal phytotherapy.
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Cucumber (Cucumis sativus L.) belongs to the Cucurbitaceae family. It is commercially 
cultivated worldwide as a seasonal vegetable crop. It is native to India, found wild in the 
Himalayas from Kumaun to Sikkimand and cultivated throughout the country (Mukherjee 
et al., 2013). 
The taxonomic classification of Cucumis sativus L. is the following 
 Kingdom: Plantae  
• Subkingdom: Tracheobionta  
 Superdivision: Spermatophyta  
• Division: Magnoliophyta  
 Class: Magnoliopsida  
 Order: Violales 
 Family: Cucurbitaceae  
 Genus: Cucumis  
 Species: Cucumis sativus L. 
Cucumber is an annually growing creeping vine. The leaves are hispidly hairy tralling or 
climbing type. Leaves are simple alternate, deeply cordate 3–5 lobed in both surfaces with 
a hairy margin denticulate. Flowers are yellow in colour; male flowers are clustered, 
bearing anthers with cohering, connective crushed or elevated above the cells whereas 
females are solitary thick covered with very bulbous based hairs. Fruits are compressed, 
elongated, ellipsoid, dorsiventrally convex and laterally ridged with variable size. Seeds 
are cream or white, testa hard and smooth. Cucumber has enclosed dicotyledonous seeds 
and it develops from a flower, and therefore it is classified as a fruit (Fig. 9 ) (Mukherjee 






Figure 9. Cucumis sativus; Family: Cucurbitaceae (Original book source: Prof. Dr. Otto Wilhelm Thomé 
''Flora von Deutschland, Österreich und der Schweiz'' 1885, Gera, Germany Permission granted to use 
under GFDL by Kurt Stueber Source). 
The medicinal properties of the cucumber have been described since ancient times. 
Different parts of the plant, e.g. leaf, fruit and seed have been explored for their 
therapeutic benefits. C. sativus fruits and seeds (Fig. 10) have important therapeutic value 
in the Indian Ayurvedic medicine. They are widely used for various skin problems 
including swelling under the eyes and sunburn. It is believed that they promote refreshing, 
cooling, healing, soothing, emollient and anti-itching effect to irritated skin. Several 
pharmacological activities including antioxidant, anti-inflammatory, antiwrinkle, 
antimicrobial, antidiabetic, and hypolipidemic potentials have been reported. Anti- 
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hyaluronidase and anti-elastase activities have been proved for its cosmetic potentials. 
(Mukherjee et al., 2013; Muruganantham et al., 2016; Park et al., 2015; Trejo-Moreno et 
al., 2018).  
 
Figure 10. C. sativus fruits and seeds (Mukherjee et al., 2013). 
Leaves, fruits and seeds of C. sativus contain numbers of phytoconstituents but the 
presence of cucurbitacins (triterpenoid substances-well-known for their bitterness and 
toxicity) is characteristic of the family Cucurbitaceae. Structurally, cucurbitacins have a 
tetracyclic cucurbitane nucleus skeleton, namely, 9b-methyl-19-nor lanosta-5-ene (Fig. 
11), which is arbitrarily divided into twelve categories (Chen et al., 2005). Despite their 
toxic nature, cucurbitacins have been proved to possess pharmacological effectiveness 
against inflammation, cancer, artherosclerosis and diabetes (Kaushik et al., 2015). 
 
 
Figure 11. Basic structure of cucurbitanes (9b-methyl-19-nor lanosta-5-ene) (Chen et al., 2005). 
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In addition to cucurbitacins, several bioactive compounds have been isolated from 
cucumber including cucumegastigmanes I and II, cucumerin A and B, vitexin, orientin, 
isoscoparin, 2″-O-(6‴-(E)-p-coumaroyl) glucoside, apigenin 7-O-(6″-O-p-
coumaroylglucoside) etc. Despite the wide use of cucumber in agricultural field, 
comparatively very few studies have been published about its chemical profile and its 
therapeutic potential (Mukherjee et al., 2013). 
 
In the third paper, to provide new scientific evidence supporting the use of Cucumber in 
traditional medicine, the main purpose was to investigate whether a water/ethanol extract 
of Cucumis sativus L. fruit can attenuate the inflammation induced by lipopolysaccharide 
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Abstract
Background: It is widely accepted the key role of endothelium in the onset of many chronic and acute vascular
and cardiovascular diseases.
In the last decade, traditional compounds utilized in “folk medicine” were considered with increasing interest to
discover new bioactive molecules potentially effective in a wide range of diseases including cardiovascular ones.
Since ancient times different parts of the Cucumis sativus L. plant were utilized in Ayurvedic medicine, among these,
fruits were traditionally used to alleviate skin problem such as sunburn irritation and inflammation. The main purpose
of the present research was, in a well-defined in vitro model of endothelial cells, to investigate whether a water/
ethanol extract of Cucumis sativus L. (CSE) fruit can attenuate the damaging effect of pro-inflammatory lipopolysaccharide
(LPS).
Methods: Cell viability, gene expression of endothelial cell markers, cytokines secretion and in vitro angiogenesis assay
were performed on porcine Aortic Endothelial Cells exposed to increasing doses (0.02; 02; 2 mg/ml) of CSE in the
presence of pro-inflammatory lipopolysaccharide (LPS 10 μg/ml).
Results: CSE reduced LPS-induced cytotoxicity and decreased the cellular detachment, restoring the expression of
tight junction ZO-1. The increase of TLR4 expression induced by LPS was counterbalanced by the presence of CSE,
while the protective gene Hemeoxygenase (HO)-1 was increased. Cucumis sativus L. inhibited the early robust secretion
of inflammatory IL-8 and GM-CSFs, furthermore inhibition of inflammatory IL-6 and IL-1α occurred late at 7 and 24 h
respectively. On the contrary, the secretion of anti-inflammatory IL-10, together with IL-18 and IFN-γ was increased.
Moreover, the in vitro angiogenesis induced by inflammatory LPS was prevented by the presence of Cucunis sativus L.
extract, at any doses tested.
Conclusions: Our results have clearly demonstrated that Cucumis sativus L. extract has attenuated lipopolysaccharide-
induced inflammatory response in endothelial cells.
Keywords: Endothelium, Cucumis sativus L., Inflammation, Hemeoxygenase-1, Cytokines, Angiogenesis
Background
Vascular integrity contributes to the maintenance of the
homeostasis of the whole organism [1]. The break of the
vascular balance causes many pathological alterations,
including cardiovascular diseases (CDVs), that represent
the principle cause of death globally [2].
Among vascular cellular components, endothelial cells
(EC) establish the inner lining of blood vessels and
perform a pivotal role in the maintenance of the vascular
integrity [1, 3–5]. Moreover endothelial cells have a key
position in the beginning, progression, control and reso-
lution of the vascular dysfunction [6–9]. Several en-
dogenous and exogenous pro-inflammatory stimuli, such
as lipopolysaccharide (LPS), induce “EC activation”. The
phenotype of activated endothelial cells promotes phenom-
ena of vasoconstriction, leukocyte adhesion, coagulation
and thrombosis. This change involves the up-regulation of
pro-inflammatory genes, including secretion of inflamma-
tory cytokines and chemokines. If the pro-inflammatory
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status is not counterbalanced by the synthesis of pro-
tective molecules, the endothelial activation converts
into the endothelial dysfunction and then in the vas-
cular disease [10, 11].
In full accordance with the principle of “Replacement”,
one of the commonly-accepted 3Rs rules (Replacement,
Reduction and Refinement) for more ethical use of ani-
mals in experimental testing, primary culture of porcine
Aortic Endothelial Cells (pAECs) were successfully used
in many different in vitro models, preceding the in vivo,
confirming swine as a relevant animal model for transla-
tional medicine [12–17].
In the last decade, traditional compounds utilized in
“folk medicine” have been considered with increasing
interest to discover new bioactive molecules potentially ef-
fective in a wide range of diseases including cardiovascular
ones. Nevertheless, to support the traditional medicine use
of these compounds, scientific informations regarding the
phytochemical or biological activity are needed. [18, 19].
Cucumber (Cucumis sativus L.) is a popular vegetable
crop member of the Cucurbitaceae family commonly
cultivated for its edible fruits. Since ancient times, differ-
ent parts of the cucumber plant have been employed in
Ayurvedic medicine, among these, fruits are traditionally
used to alleviate skin problem such as sunburn’s irrita-
tion and inflammation [20, 21]. Recently in vitro evi-
dences [22] suggested that a Cucumis sativus extract
show strong anti-oxidant capacity and ability to stability
the membrane of human red blood. Moreover, Patil [23]
demonstrated that aqueous extracts of Cucumis sativus
is efficacious on inflammatory model of ulcerative colitis
in in vivo model of Wister rats.
Nowadays no studies have investigated the effect of
Cucumis sativus L. on vascular endothelial cells. There-
fore, to provide new scientific evidence to support trad-
itional medicine use of Cucumis sativus L., the main
purpose of the present research was to investigate
whether a water/ethanol extract of Cucumis sativus L.
fruit (CSE) can attenuate the deleterious effects of LPS
in in vitro model of endothelial cells.
Methods
Chemicals and reagents
Human endothelial SFM medium, heat inactivated FBS
(Fetal Bovine Serum), antibiotic-antimycotic and Dulbec-
co’s phosphate buffered saline (DPBS) were purchased
from Gibco-Life technologies (Carlsbad CA, USA).
RNA isolation was performed with NucleoSpin RNA kit
(Macherey-Nagel GmbH & Co. KG, Düren Germany),
iScript cDNA synthesis kit and iTaq Universal SYBR
Green Supermix were used for cDNA synthesis and qPCR
analysis (Bio-Rad Laboratories Inc., Hercules, CA, USA).
All plastic supports were purchased from Falcon,
Beckton-Dickinson.
A water/ethanol extract of Cucumis sativus L. fruit
(CSE), titrated for total iminosugar acids content by
HPLC-MS (2 g/100g), was kindly provided by Naturalea
(Naturalea SA, Lugano, CH - Cuvrex batch number
CE1501).
Cell culture
Porcine Aortic Endothelial Cells (pAECs) were isolated
and maintained as previously described by Bernardini
and colleagues [12]. Briefly thoracic aortic traits were
collected in a local slaughterhouse from adult pigs. After
collection, thoracic aortic traits were washed with DPBS,
ligated at the ends, and transferred to the laboratory
within 1 h on ice. After ligation of all arterial side
branches, aortas were cannulated with modified syringe
cones and silicone tubes to set up a closed system. The
vessels were repeatedly flushed with DPBS and then
filled with a collagenase solution and incubated for
20 min at 37 °C. The cellular sospension were then cen-
trifuged at 800 x g for 10 min. The cellular pellet was re-
suspended in 1 mL human endothelial basal growth
medium (Gibco-Invitrogen, Paisley, UK) supplemented
with 5% fetal bovine serum (Gibco-Invitrogen) and 1%
antibiotics-antimicotics (Gibco-Invitrogen). Cell number
and viability (85–90%) were determined using a Burker
chamber under a phase-contrast microscope after vital
staining with trypan blue dye. Cells were maintained in a
logarithmic growth phase by routine passages every 2–
3 days at a 1:3 split ratio. To confirm their endothelial
origin, cultured cells were checked by immunocitochem-
istry for endothelial cell markers: CD31 and Caderine.
Then cells were expanded till 20th passages. All experi-
ments were performed with cells from the third to the
eighth passage. The first seeding after thawing was al-
ways performed in T-25 tissue culture flasks (3 × 105
cells/flask) and successive experiments were conducted
in 24-well plates (qPCR and western blot analysis), in
96-well assay plates (cytotoxicity) and 8-well slide cham-
ber for in vitro angiogenesis assay. Cells were cultured
in Human endothelial SFM medium, added with FBS
(5%) and antimicrobial/antimycotic solution (1×) in a 5%
CO2 atmosphere at 38.5 °C.
Cytotoxicity
Since the non-toxicity of the extract is a fundamental
pre-requisite, we first tested the cytotoxicity of the CSE
in a concentration range of 0.0002–2 mg / ml. No tox-
icity was showed at any doses tested.
pAECs were seeded in a 96 wells plate (approximately
3 × 103 cells/well) and exposed to increasing doses of
Cucumis sativus L. (CSE) (0.02; 0.2; 2 mg/ml) in pres-
ence of lipopolysaccharide (LPS) (10 μg/ml) (E. coli
055:B5, Sigma-Aldrich Co, St Louis, MO, USA) for 24 h.
Cytotoxicity was evaluated by trypan Blue exclusion dye
Bernardini et al. BMC Complementary and Alternative Medicine  (2018) 18:194 Page 2 of 9
using Countess® II FL Automated Cell Counter (Life
Technologies).
Quantitative real time PCR for ZO-1, TLR4, HO-1
pAECs were seeded in a 24 wells plate (approximately
4 × 104 cells/well) and exposed to increasing doses (0.02;
0.2; 2 mg/ml) of CSE in presence of LPS (10 μg/ml) for
1, 7 and 24 h. At the end of experimental times, treated
or control cells were collected and stored until gene ex-
pression analysis.
Total RNA was isolated using the NucleoSpin®RNA
Kit, and high quality RNA, with A260/A280 ratio above
2.0 was used for cDNA synthesis. Total RNA (500 ng)
was reverse-transcribed to cDNA using the iScript
cDNA Synthesis Kit in a final volume of 20 μL. Swine
primers were designed using Beacon Designer 2.07
(Premier Biosoft International, Palo Alto, CA, USA). Pri-
mer sequences, expected PCR product lengths and ac-
cession numbers in the NCBI database are shown in
Table 1.
Quantitative real-time PCR was performed to evaluate
gene expression profiles in CFX96 (Bio-Rad) thermal cy-
cler using SYBR green detection system. A master mix
of the following reaction components was prepared in
nuclease free water to the final concentrations indicated:
0.2 μM forward primer, 0.2 μM reverse primer, 1X iTaq
Universal SYBR Green Supermix. One μl of cDNA was
added to 19 μl of the master mix. All samples were ana-
lyzed in duplicate. The qPCR protocol used was: 10 min
at 95 °C, 40 cycles at 95 °C for 15 s and at 61 °C for
30 s, followed by a melting step from 55 °C to 95 °C
(80 cycle of 0.5 °C increase/cycle).
The expression level of interest genes was calculated
as fold of change using the 2-ΔΔCT method [24].
Western blot for TLR4 and HO-1
pAECs were seeded in a 24 wells plate (approximately
4 × 104 cells/well) and exposed to increasing doses (0.02;
0.2; 2 mg/ml) of CSE for 24 h. At the end of experimen-
tal time, cells were harvested and lysed in SDS solution
(Tris–HCl 50 mM pH 6.8; SDS 2%; glycerol 5%). Protein
Assay Kit (TP0300, Sigma) was used to determine the
protein content of cellular lysates. Aliquots containing
20 μg of proteins were separated on NuPage 4–12%
bis-Tris Gel (Gibco-Life-Technologies) for 50 min at
200 V. The proteins were then electrophoretically
transferred onto a nitrocellulose membrane by Turbo Blot
System (Bio-Rad). The blots were washed in PBS and pro-
tein transfer was checked by staining the nitro-cellulose
membranes with 0.2% Ponceau Red. Non-specific binding
on nitrocellulose membranes was blocked with 5% milk
powder in PBS-T20 (Phosphate Buffer Saline-0.1%
Tween-20) for 1 h at room temperature. The membranes
were then incubated over-night at 4 °C with a 1:500 dilu-
tion of anti-HO-1 rabbit polyclonal antibody (SPA 896
StressGen Biotecnologies Corp, Victoria BC, Canada) and
1:1000 anti TLR4 mouse monoclonal antibody (NB100–
56566 Novus Biologicals, Littleton, CO, USA). After sev-
eral washings with PBS-T20, the membranes were incu-
bated with the secondary biotin-conjugate antibody and
then with a 1:1000 dilution of an anti-biotin horseradish
peroxidase (HRP)-linked antibody.
The western blots were developed using chemilumines-
cent substrate (Super Signal West Pico Chemiluminescent
Substrate, Pierce Biotechnology, Inc., Rockford, IL, USA)
according to the manufacturer’s instructions. Chemidoc
instrument using Quantity One Software (Bio-Rad) ac-
quired the intensity of the luminescent signal of the result-
ant bands.
In order to normalize the HO-1 and TLR4 data on the
housekeeping protein, membranes were stripped (briefly:
the membranes were washed 5 min in water, then 5 min
in 0.2 M NaOH and then washed again in water) and
re-probed for housekeeping α-tubulin (1:500 of anti
α-tubulin MA1–19162, Thermo Fisher Scientific, Rock-
ford, IL, USA).
The relative protein content (HO-1 or TLR4/α-tubu-
lin) was expressed as arbitrary units (AUs).
Multiparametric enzyme-linked immunosorbent assay
(ELISA) for cytokines and chemokines
Concentration of 13 cytokines and chemokines (GM-CSF,
IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-10,
IL-12, IL-18, TNF-α) was measured by quantitative multi-
parametric ELISA (Enzyme-linked immunosorbent assay).
(Porcine Cytokine/Chemokine Magnetic Bead Panel kit,
Milliplex Map Kit, EMD Millipore Corporation, Billerica
MA USA), following the manufacturer’s instructions. The
Luminex xMAP bead-based multiplexed immunoassay
technology and MAGPIX instrument provided with xPO-
NENT 4.2 software were used.
Table 1 Primer sequence used for quantitative Real Time PCR analysis
Genes Forward (5′-3′) Reverse (5′-3′) Product size (bp) Accession Number
HPRT GGACAGGACTGAACGGCTTG GTAATCCAGCAGGTCAGCAAAG 115 AF143818
HO-1 CGCTCCCGAATGAACAC GCTCCTGCACCTCCTC 112 NM_001004027
TLR4 CAGATACAGAGGGTCATGCTTTC GGGGATGTTGTCAGGGATTTG 215 NM_001113039.1
ZO-1 AGTGCCGCCTCCTGAGTTTG CATCCTCATCTTCATCATCTTCTACAG 147 AJ318101
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Capillary-like tube formation assay
The experiments were carried out using 8-well slide
chamber (BD Falcon Bedford, MA USA) coated with un-
diluted Geltrex™ LDEV-Free Reduced Growth Factor
Basement Membrane Matrix. Extracellular matrix coat-
ing was carried out for 3 h in a humidified incubator, at
38.5 °C, 5% CO2. pAECs (8 × 10
4 cells/well) were ex-
posed to increasing doses (0.02; 0.2; 2 mg/ml) of (CSE)
in the presence of LPS (10 μg/ml) for 24 h.
At the end of experimental time, images were acquired
using a digital camera installed on a Nikon epifluores-
cence microscope (Nikon, Yokohama, Japan) and ana-
lyzed by open software Image J 64.
Statistical analysis
Each treatment was replicated three times or six times
(cytotoxicity) in three independent experiments. The
data were analysed by a one-way analysis of variance
(ANOVA) followed by the Tukey post hoc comparison
Test. Differences of at least p < 0.05 were considered sig-
nificant. Statistical analysis was carried out by using R
software (http://www.R-project.org) [25].
Results
CSE prevented LPS-induced cell death and ZO-1 reduction
The protective effect of Cucumis sativus L. extract on
LPS-induced toxicity was evaluated in pAECs. LPS treat-
ment provoked an increased number of round and de-
tached cells after 24 h (Fig. 1a), while CSE reduced the
cellular detachment in a dose dependent manner (Fig.
1b-d). Cytotoxicity assay confirmed the ability of CSE to
protect cells against LPS-induced cellular death (Fig. 1e).
Moreover, we studied the expression of ZO-1, a critical
component of tight junction scaffold; LPS induced the
downregulation of ZO-1 gene expression, while CSE re-
stored ZO-1 expression to control level at the intermedi-
ate and higher doses (Fig. 1f ).
Effect of CSE on TLR-4 and HO-1 expression
We studied the effect of CSE on the expression of the
Toll-like receptor 4 (TLR4) that is the main receptor for
LPS recognition. LPS induced a significant increase of
TLR4 mRNA after 1 and 7 h of treatment, while CSE
inhibited its expression at all doses studied (Fig. 2a).
This inhibitory effect was confirmed at protein level by
western blot analysis as shown in Fig. 2b and c. More-
over, we studied the effect of CSE on the vascular pro-
tective molecule HO-1. LPS induced HO-1 expression in
pAECs, additionally CSE increased HO-1 induction at
both mRNA (Fig. 3a) and protein level (Fig. 3b and c).
Effect of CSE on cytokine/chemokines secretion
To assess whether CSE could influence the LPS-induced
secretion of inflammatory mediators we evaluated the
presence of 13 cytokines/chemokines in the culture
medium of pAECs treated with LPS in the presence or
absence of CSE (2 mg/ml). LPS-treated endothelial cells
released significant level of Il-6, Il-8, IL-10, IL-18,
GM-CSF and IFN-γ. CSE significantly influenced these
cytokines setting; in particular, the presence of the ex-
tract decreased the concentration of GM-CSF, IL-8 and
IL-1α with a different kinetic, whereas the concentration
Fig. 1 Effect of Cucumis sativus L. extract (CSE) on LPS-induced pAECs
toxicity. a Representative images of pAECs morphology under LPS
(10 μg/ml) stimulation (b, c, d) and in the presence of increasing dose
of CSE (0.02; 0.2; 2 mg/ml). e Protective effect of CSE on LPS-induced
cytotoxicity; data shown are representative of at least three
independent experiments and represent the mean ± SEM. f CSE
restored the LPS-induced decrease of ZO-1 mRNA expression;
relative expression was calculated as fold of change in respect
to the control cells and error bar represents the range of relative gene
expression. Different letters above the bars indicate significant
differences (p < 0.05 ANOVA post hoc Tukey’s test)
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of IL-10, IL-18 and IFN-γ was increased at each experi-
mental point, as shown in Table 2. The level of IL-6
showed a precocious increase (1 h) in presence of CSE
but after 7 and 24 h, cells treated with plant extract pro-
duced less IL-6 than cells only treated with LPS. IL-1β,
IL-1ra, IL-2, IL-4, IL-12 and TNF-α were never detected
in cell culture medium (data not shown).
Effect of CSE on LPS-induced angiogenesis
We examined the effect of CSE on in vitro LPS-induced
pAECs angiogenesis in an extracellular matrix-based
assay. Cells cultured on extracellular matrix in the pres-
ence of pro-inflammatory LPS assembled in a complete
tube and network formation (Fig. 4a and e), while the in
vitro angiogenesis induced by inflammatory LPS was
prevented by the presence of Cucunis sativus L. extract,
at any doses tested (Fig. 4b-e).
Discussion
It is widely accepted the key role of endothelium in the
onset of many chronic and acute vascular and cardiovas-
cular diseases. The shift from the healthy endothelium
to the endothelial dysfunction is a complex process
involving many different factors that starts with “the ac-
tivation of endothelial cells”.
Recently, great effort is attempted to translate the poten-
tial activity of traditional compounds into the modern
therapy, in a broad range of pathologies including cardio-
vascular disease [18]. Cucumis sativus L. is a very popular
vegetable, native of India but nowadays commercially cul-
tivated all over the world. Furthermore, since ancient time,
Ayurvedic medicine has always used its fruits and seeds
for their refrigerant, haemostatic tonic properties. It is
now evident that fruits contain many interesting
phyto-complex [20, 26] that makes it an interesting
candidate for anti oxidant [27] and anti-inflammatory
action [28] but the study of their effect still requires
scientific supports.
The present study demonstrates that the protective ef-
fects reported for Cucumis sativus L., might be also medi-
ated by its protective activity on the vascular endothelium.
Being the pig an excellent model for translational re-
searches [29], in vitro approaches based on primary cell
culture are required to better define the subsequent
eventual in vivo activities to respect the 3Rs rules. We
used in vitro cultures of porcine Aortic Endothelial Cells
Fig. 2 Effect of Cucumis sativus L. extract (CSE) on LPS induced TLR4 expression. a Expression of TLR4 mRNA in pAECs treated with LPS (10 μg/ml)
for different time (1, 7, 24 h) in the presence or absence of increasing doses of CSE (0.02; 0.2; 2 mg/ml). mRNA expression of TLR4 is determined by
quantitative PCR; relative expression was calculated as fold of change in respect to the control cells and error bar represents the range of relative
expression. Different letters above the bars indicate significant differences. b Representative Western Blot of TLR4 and relative housekeeping α-tubulin
were reported. c Expression of TLR4 protein in pAECs treated with LPS (10 μg/ml) in the presence or absence of increasing doses CSE (0.02; 0.2; 2 mg/
ml); data shown are representative of at least three independent experiments and represent the mean ± SEM. Different letters above the bars indicate
significant differences (p < 0.05 ANOVA post hoc Tukey’s test)
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(pAECs), previously isolated and cultured by us to study
vascular endothelial response to different shock, includ-
ing LPS [12, 13, 30].
In the present research, LPS-induced effects on pAECs
is contrasted by the contemporary administration of
Cucumis sativus L. extract; in fact CSE protected endo-
thelial cells against LPS-induced toxicity, in a dose
dependent manner. Furthermore LPS reduced the ex-
pression of the tight junction molecule ZO-1, increasing
the number of round and detached cells. Instead,
Cucumis sativus L. extract, restored the ZO-1 expres-
sion, contributing to maintain the integrity of cellular
tight junction, as confirmed by the reduction of cellular
detachment.
It is well demonstrated that the exposure to LPS in-
duces endothelial cell activation through the binding of
a receptor complex that includes TLR4 [31–34]. In our
model TLR4 expression is increased by LPS making cells
more responsive to the stimulation, according to what
seen by other researchers [35, 36]. In contrast, the
Fig. 3 Effect of Cucumis sativus L. extract (CSE) on LPS induced HO-1 expression. a Expression of HO-1 mRNA in pAECs treated with LPS (10 μg/
ml) in the presence or absence of increasing doses of Cucumis sativus L. extract (0.02, 0.2, 2 mg/ml). mRNA expression of HO-1 as determined by
quantitative PCR. Relative expression was calculated as fold of change in respect to the control cells and error bar represents the range of relative
gene expression. Different letters above the bars indicate significant differences. b Representative Western Blot of HO-1 and relative housekeeping
α-tubulin were reported. c Expression of HO-1 protein in pAECs treated with LPS (10 μg/ml) in the presence or absence of increasing doses CSE (0.02;
0.2; 2 mg/ml); data shown are representative of at least three independent experiments and represent the mean ± SEM. (AU = Arbitrary Units) Different
letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey’s test)
Table 2 Levels of cytokines/chemokines in culture medium of pAECs stimulated with LPS (10 μg/ml) in the presence or absence of
Cucumis sativus L. extract (CSE 2 mg/ml). Data shown are representative of at least three independent experiments and represent
the mean ± SEM. Significant differences are indicated by (p < 0.05) *, and (p < 0.001) by ** nd not detectable
ng/ml 1 h 7 h 24 h
CSE-/LPS+ CSE+/LPS+ CSE-/LPS+ CSE+/LPS+ CSE-/LPS+ CSE+/LPS+
IL-1α nd nd nd nd 0.0592 ± 0.0019 0.0140 ± 00002**
IL-6 nd 0.1574 ± 0.0064 4.3163 ± 0.0893 3.3889 ± 0.0835* 8.0129 ± 0.3067 3.9270 ± 0.0335**
IL-8 6.3445 ± 0.4821 2.3809 ± 0.0434** > 50 24.2300 ± 2.2100 31.5600 ± 3.8210* 25.1500 ± 2.7210
IL-10 0.0077 ± 0.0023 0.0355 ± 0.0010** 0.0187 ± 0.0025 0.0395 ± 0.0034* 0.0209 ± 00017 0.0400 ± 0.0056**
IL-18 0.0319 ± 0.0021 0.1796 ± 0.0049** 0.0572 ± 0.0011 0.1897 ± 0.0033** 0.0606 ± 0.0034 0.1913 ± 0.0056**
GM-CSF 0.1083 ± 0.0071 nd 0.1895 ± 0.0221 nd 0.2061 ± 0.0094 0.0021 ± 0.0037**
IFN-γ 0.0501 ± 0.0436 1.5529 ± 0.0292** 0.2654 ± 0.0889 0.5230 ± 0.0725* 0.0725 ± 0.0378 0.3522 ± 0.0340**
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presence of Cucumis sativus L. extract, inhibited the
LPS-induced expression of TLR4.
The inflammatory signalling driven by TLR4 in
endothelial cells goes through the activation of NF-κB
and the consequently induction or shutdown of sev-
eral genes including those for cytokines/chemokines
synthesis [37].
The presence of CSE in the culture medium con-
trasted early the robust secretion of inflammatory IL-8
and GM-CSFs; while inhibition of inflammatory IL-6
and IL-1α occurred late at 7 and 24 h respectively. On
the contrary, the anti-inflammatory IL-10 is increased
together with IL-18 and IFN-γ.
Since the production and function of cytokines overlaps,
what is the meaning of our results? Considering that in
vivo endothelial cells mainly produce IL-6 and IL-8 and
being, among the major functions of these cytokines, the
induction of angiogenesis [11], the anti-angiogenic effect
of CSE, evidenced by the in vitro-angiogenesis assay, is in
agreement with the inhibition of these cytokines. More-
over interleukin 18 (IL-18), firstly described as a novel
cytokine that stimulates interferon-γ (IFN-γ) production,
possessed potent antitumor effects achieved by the inhib-
ition of angiogenesis in vivo [38], so the increase of IL-18
in our model, could also contribute to a reduction in in-
flammatory angiogenesis.
Overall, our results demonstrate that the extract of
Cucumis sativus L. influenced the secretion of cyto-
kines/chemokines trough the reduction of TLR4 expres-
sion; moreover, the effect of this modulation inhibited
the inflammation-induced angiogenesis. Overall, these
important results suggest that Cucumis sativus L. extract
could be a very interesting candidate in counteracting
inflammatory pathologies in which TLR play a crucial
modulatory role.
Furthermore, to avoid that the endothelial cell activa-
tion results in dysfunction, the induction of protective
genes must be strictly regulated. Among protective
genes, Hemeoxygenase (HO)-1, the rate-limiting enzyme
in the heme catabolism, has been demonstrated to
present important beneficial roles in the vasculature
[39]; in particular HO-1 exerts antiapoptotic, antioxi-
dants, antithrombotic and anti-atherogenic effects [39].
Our previous reports showed the LPS ability to induce
HO-1 expression [12]; in the present research we dem-
onstrated that Cucumis sativus L. extract increased the
expression of vascular protective HO-1. Moreover, the
role of HO-1 in angiogenesis is intriguing in fact HO-1
activity is necessary for VEGF-induced angiogenesis,
whereas HO-1 has the opposite effect in the pathological
angiogenesis [39]. Therefore, in our model, the increase
of HO-1 could exert protective effect including the in-
hibition of LPS-induced inflammatory angiogenesis.
Conclusions
Our results demonstrate the efficacy of a water/ethanol ex-
tract of Cucumis sativus L. fruit to protect vascular endo-
thelial cells against LPS-challenge: decreasing LPS-induced
TLR4 expression, influencing cytokines secretion, in-
creasing the expression of protective HO-1. Moreover,
the presence of Cucumis sativus L. extract inhibited the
LPS-induced cellular toxicity and inflammation-induced
angiogenesis. These impressive and robust results propose
the Cucumis sativus L. extract as a promising natural
compound in vascular endothelium protection.
Fig. 4 Effect of Cucumis sativus L. extract on LPS-induced angiogenesis. pAECs were cultured on a extracellular matrix with LPS (10 μg/ml) in the
absence (a) or presence of increasing doses (0.02; 0.2; 2 mg/ml) of Cucumis sativus L. extract (b, c, d respectively) for 18 h. LPS induced a capillary
like network (a, e) while CSE reduced LPS-induced angiogenesis at any doses tested (b-e). Data shown are representative of at least three independent
experiments and represent the mean ± SEM. Different letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey’s test)
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Comparative medicine: dog as spontaneous animal model 
Man's best friend, Canis familiaris, plays an important role in the field of comparative 
medicine. The unique breeding history of the domestic dog offers an exceptional 
opportunity to explore the genetic basis of disease susceptibility, morphological variation 
and behavioural traits. The position of the dog within the mammalian evolutionary tree 
also makes it an important guide for comparative analysis of the human genome. 
The history of the domestic dog traces back at least 15,000 years, and mitochondrial DNA 
(mtDNA) analyses have probably suggested dating far back to 100,000 years ago, until 
its original domestication in East Asia from the grey wolf, the dog's direct ancestor. 
Humans and dogs evolved through a mutually beneficial relationship, sharing living 
environment and food sources. In recent centuries, humans have selectively bred dogs 
that excel at herding, hunting and obedience. During domestication process, dog's 
behavioural patterns changed and have created breeds rich in behaviours that mimic 
human ones and support our needs. Dogs have also been bred for desired physical 
characteristics such as body size, skull shape, leg length, coat colour and texture, 
producing breeds with closely delineated morphological features. This evolutionary 
experiment has generated diverse domestic breed under strong selection, each dog breed 
represents an isolated breeding population and harbouring more morphological variability 
than those present within the remainder of the family Canidae (Lindblad-Toh et al., 2005; 
Parker et al., 2010). 
As a consequence of these stringent breeding programmes and periodic population 
bottlenecks (for example, during the World Wars), many of the ∼400 modern dog breeds 
also show a high prevalence of specific diseases, including cancers, blindness, heart 
disease, cataracts, muscular dystrophy, autoimmune disease, epilepsy, hip dysplasia and 
deafness. Many canine diseases are caused by mutations in the same genes as the 
corresponding diseases in humans. Moreover, most of dog's diseases are also frequently 
seen in the human population, with similar clinical manifestations. The high prevalence 
of specific diseases within certain breeds suggests that a limited number of loci underlies 
each disease, making their genetic dissection potentially more tractable in dogs than in 
humans (Lindblad-Toh et al., 2005). 
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Except for human, dog is the most highly studied animal in medical practice, with often 
available detailed family history and pathology data. Through the efforts of the American 
Kennel Club (AKC) and similar organizations worldwide, extensive genealogies and 
genetic data are easily accessible for most purebred dogs (Lindblad-Toh et al., 2005). 
The dog genome is more similar to human genome than mouse genome, therefore, more 
of the human genomic sequence can be aligned to the genome of the dog than that of the 
mouse. Dogs have approximately the same number of genes as humans, most of them 
being close orthologues. Several canine diseases are caused by mutations in the same 
genes as the corresponding diseases in humans (Hytönen and Lohi, 2016). The 
sequencing of the canine genome and subsequent development of powerful gene 
discovery tools has remarkably facilitated gene discoveries in disease, morphology and 
behaviour. Currently, over 300 variants that underlie canine Mendelian disorders are 
recorded in the public database Online Mendelian Inheritance in Animals (OMIA) 
(OMIA, 2011) and novel mutations are continually discovered (Donner et al., 2016; 
Lindblad-Toh et al., 2005; Parker et al., 2010). 
Moreover, pet dogs share also the environmental living and are exposed to the same 
environmental risk factors of their owners and are thus not only affected by genetic traits 
but also by “life style”.  Many of spontaneously occurring canine pathological disorders 
are analogous to human diseases such as diabetes, cancers, epilepsies, eye diseases and 
autoimmune diseases, and several rare monogenic diseases (Donner et al., 2016; Hytönen 
and Lohi, 2016).  
Consequently, dog becomes an important comparative model for the development of new 
therapies for both species, but also for the better understanding of the molecular 




Figure 11. Various clinical, genetic, physiological and environmental characteristics in dogs make them 
excellent comparative models for facilitating the understanding and treatment of human disorders 
(Hytönen and Lohi, 2016). 
In human oncology research, murine cancer models such as xenografts and transgenic 
mouse models have been extremely useful in the study of the complexity of human cancer 
biology. However, sometimes the tumour development and biological responses observed 
in murine models are not predictive of what happens in human tumours. Therefore, there 
is an increasing need for a more appropriate, spontaneous animal model that reflects the 
biologic complexity of human cancer. In this regard, companion animals (pet dogs and 
cats) seem to have many desired characteristics that fill the gap between in vitro and in 
vivo studies. Spontaneous tumours in companion animals, particulars in dogs, are a 
unique and underused resource as models for human cancer biology and for translational 
cancer therapeutics. Naturally occurring tumours in dogs have clinical presentation, 
histology, disease progression, and response to treatment similar to human cancers that 
are difficult to reproduce in other model systems (Pinho et al., 2012). Cancers in pet dogs 
often mirrors the biology and heterogeneity of human disease, including complex 
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interactions between the immune system and tumour cells, significant heterogeneity, 
development of chemotherapy resistance, and metastasis resulting in patient death 
(Gardner et al., 2016). The increasing interest of cancer researchers in this type of animal 
models and the growing number of publications in veterinary oncology makes 
comparative oncology of primary importance in translational medicine, allowing for the 
rapid and valid flow of data for clinical application in humans (Pinho et al., 2012). 
Recently advances in the development of genome techniques and commercially available 
high-throughput methodologies, like genotyping microarray, specific for dogs have 
increased the ability to understand mechanism and characterize canine cancers. 
Importantly, specific molecular pathways of human tumour are frequently observed in 
canine cancers, offering the opportunity to target those mechanisms in dogs and develop 
accurate preclinical assessment of novel therapeutics. The similarities between cancer in 
dogs and humans underscore the value of comparative and translational research for the 
benefit of both species. Clinical trials evaluating novel therapeutics in dogs affected by 
cancer provide dogs with state-of-the-art therapy at little or no cost and generate critical 
new data with direct applicability to subsequent human clinical studies. Consequently, 
international collaborative initiatives, as well as biomedical industry entities, now 
leverage client-owned dogs with spontaneous tumours to address central questions 
regarding the biologic activity, adverse event profile, appropriate dose/regimen, and 
pharmacodynamic/pharmacokinetic endpoints for novel cancer treatments with the 
ultimate goal of accelerating their application to human cancers (Gardner et al., 2016). 
Dogs naturally develop cancers that share many characteristics with human malignancies, 
in particular osteosarcoma (Fenger et al., 2014), lymphoma (Marconato et al., 2013), 
leukaemias (Figueiredo et al., 2012; Gardner et al., 2016), mammary cancer (Liu et al., 





Osteosarcoma (OSA) is the most common primary bone tumour in both people and dogs, 
but it is significantly more prevalent in dogs, with a reported incidence of 13.9/100,000 
in dogs in contrast to 1.02/100,000 in humans. OSA commonly occurs in older dogs 
(median age 7 years); however, a bimodal distribution is present with a small peak in 
young dogs (average age 1 year). This is in contrast to human OSA, which is more 
frequent in adolescence (10- to 14-year-old age group) (Fenger et al., 2014). Amputation 
and adjuvant chemotherapy increase median survival times to 8-12 months from the 3-4 
months generally achieved with amputation alone; however, 90% of dogs are euthanized 
within 2 years of diagnosis (Withrow et al., 2012). Moreover,  the prognosis for OSA  is 
caution in children; the overall 5-year survival rate is 67% in the nonmetastatic disease  
and 10-30% if metastases are found at initial diagnosis (Fenger et al., 2014). Genes and 
signalling-pathway alterations to disease pathogenesis are highly conserved in both the 
human and canine OSA, confirming the relevance of canine OSA as spontaneous animal 
model for OSA in paediatric research. Comparative genomic analyses have demonstrated 
abnormalities similar in human and dog OSA, this discover has identified novel molecular 
drivers that may be interesting targets for therapeutic intervention. Dysregulation of 
specific candidate genes implicated in the etiopathogenesis of OSA are found in both 
species, including mutations in the tumour suppressor genes p53, RB1, and PTEN and 
alterations of the oncogenes MYC and MET (Fenger et al., 2014). In conclusion, together 
these data suggest that the integration of dogs with OSA into comparative and 
translational cancer research has the potential to identify shared and novel molecular 
targets for therapeutic intervention, lending additional insight into the biology of OSA 
and ultimately advancing the care of children affected by this dangerous disease (Gardner 




D-17 canine osteosarcoma cell line 
Canine Osteosarcoma cells line (D-17) was purchased from the “Istituto Zooprofilattico 
Sperimentale della Lombardia e dell’Emilia Romagna - Sez. Brescia”. These cells were 
obtained from a metastasis to the lung of an osteosarcoma in a 11-year old female poodle 
dog (Riggs et al., 1974).  
 
Figure 12. D-17 canine osteosarcoma cell line. 
As reported in literature, D-17 canine osteosarcoma cells were a consolidate in vitro 
model for the studies on dog osteosarcoma (Gebhard et al., 2018, 2016; Lopez et al., 
2018) and in comparative medicine (Bergeron et al., 2013; Shahi et al., 2015). Moreover, 
D-17 were used as an in vitro model for toxicology and pharmacology studies, to evaluate 
the efficacy of drugs and natural compounds (Helmerick et al., 2014; Seo et al., 2012; 
Zhao et al., 2018). 
In this thesis, the cytotoxicity and anti-proliferative effects of a hydroalcoholic extract 
obtained from Artemisia annua L., used for centuries in Chinese Traditional Medicine 
and recently proposed as antimalaria and antitumoral drug, were evaluated on canine 




Artemisia annua  
Artemisia annua L. is a member of the Asteraceae family of plants (formerly 
Compositae). Since ancient time, A. annua has been used in Traditional Chinese Medicine 
(TCM) for the treatment of several diseases. It is native to China but is widely distributed 
in the temperate, cool temperate and subtropical zones of the world. The Chinese name 
of the plant is Qinghao, which means green herb, but it is also known as sweet wormwood, 
Chinese wormwood sweet, annual wormwood, annual sagewort, annual mugwort, and 
sweet sagewort (Brown, 2010).  
The taxonomic classification of Artemisia annua L. is the following 
 Kingdom: Plantae  
• Subkingdom: Tracheobionta  
 Superdivision: Spermatophyta  
• Division: Magnoliophyta  
 Class: Magnoliopsida  
 Order: Asterales 
 Family: Asteraceae  
 Genus: Artemisia 
 Species: Artemisia annua L. 
A. annua is an annual herb, that can naturally grow to 30-100 cm high. The stem is erect, 
ribbed, brownish or violet-brown. Leaves are alternate, alveolate, dark green, or brownish 
green. Odour is characteristic and aromatic, while the taste is bitter. It is characterized by 
large panicles of small globulous capitulums (2-3mm diameter), with whitish involucres, 
and by pinnatisect leaves which disappear after the blooming period, characterised by 




Figure 13. Artemisia annua L. (Original sources: Vuyck, L. (1906) Flora Batava. 22. Band. Vincent 
Loosjes, Haarlem. Tafel 1697 and Einjähriger Beifuß ''Artemisia annua'' photographed by Kristian 
Peters). 
In the western medicine, the notoriety of A. annua is linked to the antimalarial action 
against the parasite Plasmodium falciparum. In 1972, from A. annua, Youyou Tu, a 
Chinese pharmaceutical chemist, isolated artemisinin following low temperature 
extraction. Nowadays, artemisinin, its derivatives and Artemisinin Combination Therapy 
(ACT) belong to the established standard treatments of malaria worldwide. For this 
important discover, Youyou Tu was awarded the Nobel Prize in Physiology or Medicine 
in 2015. 
Over 600 phytochemicals have been identified as constituents of A. annua L (Brown, 
2010). The chemical composition of A. annua consists of volatile and non-volatile 
constituents. The volatile components are mainly attributable to essential oils with the 
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percentage of the latter being 0.2-0.25%. The main non-volatile ingredients include 
sesquiterpenoids, flavonoids and coumarins, together with proteins (such as β-
galactosidase, β-glucosidase) and steroids (e.g. β-sitosterol and stigmasterol) (Brown, 
2010; WHO, 2006).  
This chemical composition is common among Artemisia genus, that counts more than 
200 species, but the major and unique constituent of A. annua is the sequiterpene 
artemisinin (Brown, 2010).  
Artemisinin is a sesquiterpene trioxane lactone, which contains an endoperoxide bridge 
essential for its biological activity (Fig. 14).  
 
Figure 14. Chemical structures of artemisinin and its derivatives (Ho et al., 2014). 
Artemisinin can be extracted from dried leaves, but its content is highly variable, ranging 
anywhere between 0.01% and 0.8% of the dry weight, depending on variety, environment 
and growth conditions, and can even be as high as 1.4% in some cultivated strains 
(Brown, 2010; Golenser et al., 2006; Van Der Kooy and Sullivan, 2013). The low amount 
of artemisinin extracted from the plant can represent a serious limitation for the 
commercialization of the drug. Moreover, artemisinin has low hydro and liposolubility, 
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and has a limited bioavailability. Different approaches have been used to increase content 
of artemisinin; metabolic and genetic engineering strategies have been developed not only 
in cell/tissue plant cultures but also in transgenic plants (Badshah et al., 2018; Brown, 
2010; Golenser et al., 2006; Sun et al., 2017). In the last 30 years, to resolve these 
problems, several semisynthetic artemisinin derivatives (artemisinins) were developed 
(Fig. 14). 
Although developed as antimalarials, artemisinin and its semisynthetic derivatives have 
been studied for many other therapeutic properties (Fig. 15). 
 
Figure 15. Bubble map outlining various biological activities of artemisinins and their potential clinical 
applications in different diseases (Ho et al., 2014). 
Artemisinin and its derivatives have been reported to possess strong inhibitory effects 
against viruses (e.g. Human cytomegalovirus), protozoa (e.g. Toxoplasma gondii), 
helminths (e.g. Schistosoma species and Fasciola hepatica) and fungi (e.g. Cryptococcus 
neoformans). Moreover, artemisinins have demonstrated anti-inflammatory effects and 
have been evaluated in autoimmune diseases, allergic disorders and septic inflammation. 
The anti-inflammatory effects of artemisinins have been attributed to the inhibition of 
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Toll-like receptors, Syk tyrosine kinase, phospholipase Cγ, PI3K/Akt, MAPK, STAT-
1/3/5, NF-κB, Sp1 and Nrf2/ARE signaling pathways (Ho et al., 2014). 
Since the late 1990s, anticancer properties of artemisinins have been well known and 
there has been rapid multiplication of in vitro/in vivo studies, case reports and clinical 
trials on the antitumor properties of artemisinins (Bhaw-Luximon and Jhurry, 2017).  
The endoperoxide moiety is the key of the bioactivity of artemisinin-type drugs. Its 
cleavage leads to reactive oxygen species (ROS) formation and induces oxidative stress. 
Furthermore, in the presence of ferrous iron or reduced heme, artemisinins can convert 
itself into cytotoxic carbon-centred radical, a highly potent alkylating agent, to induce 
direct oxidative damage to cancer cells (Bhaw-Luximon and Jhurry, 2017; Efferth, 2017).  
Oxidative stress and DNA damage block cell cycle progression and induce various cell 
death modes: apoptosis, necrosis, necroptosis, autophagy and ferroptosis, confirming the 
crucial role of iron for artemisins anticancer activity (Efferth, 2017). 
 
 
Figure 16. Overview of the anti-cancer mechanisms of action for artemisinins (Ho et al., 2014). 
Like several natural products, another important advantage of artemisinin and its 
derivatives is that they act in a multi-specific manner against tumours. Indeed, 
artemisinins reduce cell proliferation, inhibit angiogenesis and tissue invasion of the 
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tumour, as well as cancer metastasis (Fig. 16). In particular, artemisinis act to tumour-
related signal transduction pathways (e.g. Wnt/β-catenin pathway, AMPK pathway), 
signal transducers (NF-κB, MYC/MAX, AP-1, CREBP, mTOR etc) and proteolytic 
enzymes, such as MMPs. Complex interactions through different pathways may enhance 
the anticancer effect of artemisinins (Bhaw-Luximon and Jhurry, 2017; Efferth, 2017; Ho 
et al., 2014). 
 
In the fourth preliminary paper, the cytotoxicity and anti-proliferative effects of a 
hydroalcoholic extract obtained from Artemisia annua L., were evaluated in vitro on 
canine osteosarcoma cell line (D-17), considering the importance of canine osteosarcoma 
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Preliminary study to evaluate the cytotoxic effects of 
Artemisia annua L. and artemisinin on D-17 canine 
osteosarcoma cell line 
Abstract 
Artemisia annua L. has been used for centuries in Chinese Traditional Medicine. 
Although developed as antimalarials, its active compound artemisinin and its semi-
synthetic derivatives have been also investigated for their anticancer property, with 
interesting and promising results. Artemisinin is a sesquiterpene trioxane lactone, 
which contains an endoperoxide bridge essential for its activity. Reduced heme or 
ferrous iron are believed to be responsible for the activation of the endoperoxide 
bond, leading to the formation of ROS and carbon centred radicals, that act as 
alkylating agents. In veterinary medicine, canine osteosarcoma represents a highly 
aggressive tumour that often leads to therapeutic failure due to lung metastasis and 
development of chemo-resistance, highlighting the urgent need of novel therapies. 
Naturally occurring tumours in dogs have many clinical and biological similarities 
to the human counterpart and make the dog an important spontaneous animal model 
in comparative medicine. The aims of this research were to evaluate the cytotoxicity 
and the anti-proliferative effect of pure artemisinin and a commercial 
hydroalcoholic extract obtained from A. annua on canine osteosarcoma cell line (D-
17). The last aim was to optimize an analytical protocol for the determination of 
intracellular iron in D-17 cells. Both artemisinin and hydroalcoholic extract induced 
cytotoxic effect in a dose-dependent manner. Pure artemisinin caused an increase 
of cells in S phase, whereas the hydroalcoholic extract induced an evident increase 
in G2/M phase. A significant decrease of iron concentration was measured in D-17 
cells treated with pure artemisinin and hydroalcoholic extract compared to 
untreated cells. In conclusion, although preliminary, the data obtained in this study 
are indicative of a more potent cytotoxic activity of the hydroalcoholic extract than 
pure artemisinin, indicating a possible synergistic effect of the phytocomplex. 
Considering the similarities between human and canine osteosarcoma, progress in 
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deepening knowledge and improving therapeutic protocols will probably be 
relevant for both species, in a model of reciprocal translational medicine. 
Introduction  
Since ancient time, Artemisia annua L. (family Compositae) has been used as 
medicinal plant in the treatment of several diseases in Traditional Chinese Medicine 
(Brown, 2010). Nowadays, the reputation of A. annua is linked to its antimalarial 
activity. In 2015, Youyou Tu was awarded the Nobel Prize in Physiology or 
Medicine for isolating the active molecule artemisinin from A. annua. Currently, 
artemisinin, its derivatives and Artemisinin Combination Therapy (ACT) belong to 
the established standard treatments of malaria worldwide (Efferth, 2017). Over 600 
phytochemicals have been identified as constituents of A. annua, but its 
phytochemistry is dominated by sesquiterpenoids, flavonoids and coumarins, 
together with proteins (such as β-galactosidase, β-glucosidase) and steroids (e.g. β-
sitosterol and stigmasterol) (Brown, 2010). However, A. annua is distinguished 
from the other 200 species of the Artemisia genus by the exclusive presence of 
artemisinin, the active compound extracted from dried leaves (WHO monograph on 
good agricultural and collection practices (GACP) for Artemisia annua L.). 
Artemisinin is a sesquiterpene trioxane lactone, which contains an endoperoxide 
bridge essential for its biological activity. The low amount of artemisinin extracted 
from the plant, its low hydro and liposolubility and its limited biodisponibility can 
represent a serious limitation for the standardization and commercialization of the 
drug. In the last 30 years, several semisynthetic artemisinin derivatives were 
developed with different strategies, including genetic engineering (Badshah et al., 
2018; Brown, 2010; Sun et al., 2017). Although developed as antimalarials, 
artemisinin and its semisynthetic derivatives, have been also investigated for many 
other therapeutic properties, such as antiviral, antimicrobial and anti-inflammatory 
activities (Ho et al., 2014). However, since the late 1990s, anticancer properties of 
artemisinins have been well known and there has been a rapid increase of in vitro 
and in vivo studies, case reports and clinical trials on the antitumor properties of 
artemisinins (Bhaw-Luximon and Jhurry, 2017). The endoperoxide moiety is the 
key of the bioactivity of artemisinin-type drugs. Its cleavage leads to reactive 
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oxygen species (ROS) formation and induces oxidative stress. Furthermore, in the 
presence of ferrous irons or reduced heme, artemisinin can convert itself into 
cytotoxic carbon-centred radical, a highly potent alkylating agent, to induce direct 
oxidative damage to cancer cells (Bhaw-Luximon and Jhurry, 2017; Efferth, 2017). 
Complex interactions through different pathways may enhance the anticancer effect 
of artemisinins. Indeed, artemisinins induce apoptosis and ferroptosis, reduce cell 
proliferation through cell cycle arrest, inhibit angiogenesis and tissue invasion of 
the tumour, as well as cancer metastasis (Bhaw-Luximon and Jhurry, 2017; Efferth, 
2017; Ho et al., 2014).  
In veterinary medicine, osteosarcoma (OSA) accounts for 2-5% of all canine 
malignancies (Farcas et al., 2014) and for 80-85% of all bone tumours (Chun and 
de Lorimier, 2003; Morello et al., 2011). OSA is characterized by locally aggressive 
and highly metastatic behaviour, that leads to early mortality (Morello et al., 2011; 
Szewczyk et al., 2015). Affected bone is destroyed by the tumour, that typically 
extends to surrounding soft tissues. Metastases spread mainly via haematogenous 
route and mostly to the lungs (Morello et al., 2011; Pollard and Kitchen, 2017; 
Szewczyk et al., 2015). Other metastatic sites are represented by other bones, 
visceral organs, brain, subcutaneous tissue and skin. Metastasis to regional lymph 
nodes are quite uncommon (4.4-9%) (Morello et al., 2011). Treatment for OSA 
involves surgery to remove primary tumours and on occasion distant metastasis. 
Surgery involves either amputation of the limb or limb salvage/sparing procedures. 
However, dogs treated with surgery alone have a short median survival time 
(Simpson et al., 2017). Surgery combined with neoadjuvant and/or adjuvant 
chemotherapy prolongs the survival of dogs with OSA and the protocols include 
doxorubicin, cisplatin, carboplatin and lobaplatin used alone or in combination 
(Morello et al., 2011; Simpson et al., 2017; Szewczyk et al., 2015).   
Spontaneously occurring OSA in dogs have clinical presentation, biological 
behaviour, response to treatment and disease progression similar to human OSA, 
that are difficult to reproduce in other model systems (Fenger et al., 2014; Gardner 
et al., 2016; Pinho et al., 2012). OSA is the most common primary malignancy of 
bone both in dogs and humans. It is significantly more prevalent in dogs, with an 
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incidence rate 27 times higher in dogs than in people. OSA commonly occurs in 
older dogs (median age 7 years), while in humans is more common in adolescence 
(10- to 14-year-old age group) (Gardner et al., 2016; Simpson et al., 2017). The site 
of OSA development in children and dogs is strikingly similar, with a predilection 
for the weight-bearing region of long bones. Approximately 75% of canine OSA 
occurs in the appendicular skeleton, with the most common sites in the distal radius 
and proximal humerus. In human OSA, long bones are affected in up to 90% of 
cases, with the distal femur, proximal tibia, and the proximal humerus being the 
most common locations (Fenger et al., 2014; Simpson et al., 2017). Furthermore, 
mutations of specific genes involved in the etiopathogenesis of OSA are found in 
both species, including mutations in the tumour suppressor genes p53, RB1 and 
PTEN and alterations of the oncogenes MYC and MET (Gardner et al., 2016). 
However, therapeutic failures are recurrent in both dogs and humans and are mainly 
due to the development of multiple resistance and metastatic spread, making the 
development of new therapies essential. 
Therefore, to provide new scientific evidence to support antitumor activity of A. 
annua L. in in vitro animal model, the main purposes of the present research were 
to evaluate the cytotoxicity and the effects on cell cycle of pure artemisinin and a 
commercial hydroalcoholic extract obtained from A. annua on canine osteosarcoma 
cell line (D-17). Considering the crucial role of iron on artemisinin activity, the last 
aim was to optimize an analytical protocol for the determination of intracellular iron 
in D-17 cells. 
Materials and Methods 
Chemicals and reagents 
All reagents were obtained from Sigma Aldrich (St. Louis, MO, USA), if not 
otherwise specified, and were Ultrapure grade, included 98% pure artemisinin 
(CAS number: 63968-64-9). Minimum Essential Media (MEM), heat inactivated 
fetal bovine serum (FBS) and Dulbecco’s phosphate buffered saline (DPBS) were 
purchased from Gibco-Life technologies (Carlsbad CA, USA). A commercial 
hydroalcoholic extract obtained from A. annua and composed by 65% ethanol, 20% 
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of aerial parts and water. This extract contains 2 mg artemisinin/ml (corresponding 
to 7 mM) as declared by the producer. All plastic supports were purchased from 
Falcon, Beckton-Dickinson (Franklin Lakes, NJ, USA). 
Cell culture and treatment 
Canine osteosarcoma cells line (D-17) was purchased from the “Istituto 
Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna – Sez. 
Brescia”. Cells were cultured in Minimum Essential Media (MEM) added with 
2 mM L-Glutamine and FBS (5%) in a 5% CO2 atmosphere at 37°C. The first 
seeding after thawing was always performed in T-75 tissue culture flasks (4x106 
cells/flask) and successive experiments were conducted in T-25 flasks (cell cycle 
analysis and iron quantification) and in 96-well assay plates (cytotoxicity). 
Artemisinin was dissolved in DMSO to obtain a 50 mM stock solution then diluted 
in culture medium to obtain the required concentrations. Hydroalcoholic extract of 
A. annua was directly diluted in culture medium to obtain the required 
concentrations. For each treatment, the same concentration of the specific vehicle 
was used as control, DMSO for artemisinin and a solution of 65% ethanol for 
hydroalcoholic extract. 
Cytotoxicity 
D-17 were seeded in a 96 wells plate (approximately 1.5 × 104 cells/well) and 
exposed for 24 h to increasing concentration of pure artemisinin (50, 100, 250, 500, 
750, 1000, 2000 µM) or increasing doses of A. annua hydroalcoholic extract 
corresponding to artemisinin concentrations of 14, 35, 70, 140, 280, 420, 700 µM, 
on the base of the declared concentration of 2 mg artemisinin/ml in hydroalcoholic 
extract. Cytotoxicity was measured using tetrazolium salt (In Vitro Toxicology 
Assay Kit, MTT based). The formazan absorbance was measured at a wavelength 
of 570 nm, using Infinite® F50/-Robotic Absorbance microplate readers TECAN 
(Life Science). The background absorbance of multiwall plates at 690 nm was also 
measured and subtracted from the 570 nm measurements. 
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The concentrations of artemisinin required for 50% inhibition of cell viability (IC50) 
were calculated by Prism Graph Pad software and the IC50 values were used for 
subsequent experiments. 
Cell cycle analysis  
For the analysis of cell cycle in flow cytometry, aliquots of 1x106 cells in duplicate, 
for each treatment (IC50 standard artemisinin, IC50 A. annua hydroalcoholic extract) 
were washed from growth medium by centrifuging at 240 x g for ten minutes. Then, 
the resulting pellet was resuspended in 1 ml of a solution containing 0.1% sodium 
citrate, 0.1% Nonidet, 10 µg/ml of RNAse and 50 µg/ml of propidium iodide (final 
concentration 1x106 cells/ml). The PI fluorescence is acquired by flow cytometer 
(Epics Beckman Coulter) equipped with an Argon Ion laser tuned at 488 nm. PI red 
fluorescence (600 nm) is analysed on a linear scale and data analyses is performed 
using the software program “ModFit” (USA). 
Iron quantification  
For the iron determination was used a Spectra AA-20 atomic absorption 
spectrometer (Varian) equipped with a GTA-96 graphite tube atomizer and the 
sample dispenser. The optimization of the analytical method was obtained as it is 
given by (Tüzen, 2003) with minor changes: the graphite tubes employed were 
coated GTA tubes (Agilent Technologies, Germany), the hollow cathode lamp 
current was 7 mA and measurements were performed at 248.3 nm resonance lines 
using a spectral slit width of 0.2 nm. During spectrophotometer readings, internal 
argon flow rate in the partition graphite tubes was maintained at 300 ml/min and 
was interrupted in the atomization phase. Ramp and hold times for the drying, 
pyrolysis, atomization and cleaning temperatures are reported in Table 1 and were 
optimized to obtain maximum absorbance without significant background 
absorption so no background correction was necessary. For the same reasons, 




Table 1. Furnace conditions for the determination of iron in D-17 cells. 
Phases of 





Drying 1 110 1 20 
Drying 2 130 5 30 
Pyrolisis 1100 15 10 
Atomization 2200 0.6 5 
Cleaning 2600 1 2 
 
The calibration curve was obtained by diluting 1 mg/ml standard stock solution of 
iron (BDH Chemicals, Poole, England) with MilliQ water to obtain working 
standards containing 0, 20, 40 and 60 ng/ml of iron and by plotting the absorbance 
at 248.3 nm against iron concentrations. The equation of the curve was y = 0.0109x 
and the calculated regression coefficient (r) was 0.993. 
For the quantification of iron, for each treatment (IC50 standard artemisinin, IC50 A. 
annua hydroalcoholic extract), D-17 cells were harvested, counted and centrifuged 
at 800 x g for 10 min. The pellet was washed twice with DPBS, then resuspended 
in a solution of 1 M HNO3 overnight, at a final concentration of 1x106 cells/ml. The 
samples were centrifuged at 1500 x g for 10 min to precipitate cellular debris. The 
detection limit (LOD), defined as the concentration corresponding to 3 times the 
standard deviation of 6 blanks, was 0.8 ng/ml. Iron concentration is reported as ng 
Fe/1 x 106 cells. 
Statistical analysis  
Cytotoxicity assay was performed on six replicates and IC50 concentrations were 
obtained by Prism Graph Pad software. Data of iron quantification were analysed 
with a one-way analysis of variance (ANOVA) followed by the Tukey post hoc 
comparison Test. Data of cell cycle were analysed with two-way analysis of 
variance (ANOVA) followed by the Bonferroni multiple comparisons. Differences 
of at least p < 0.05 were considered significant. Statistical analysis was carried out 




Effect of Artemisia annua hydroalcoholic extract and artemisinin on cell 
viability  
The effect of artemisinin pure standard and A. annua hydroalcoholic extract was 
evaluated on D-17 cells by MTT assay. Both artemisinin and hydroalcoholic extract 
induced a decrease of cell viability at all concentrations and exerted cytotoxic effect 
in a dose-dependent manner. Both provoked an increased number of round and 
detached cells after 24 h, more evident in the presence of hydroalcoholic extract 
(Fig. 1D and E). Data obtained from MTT analyses were elaborated to assess the 
concentration of artemisinin required for 50% inhibition of cell viability (IC50): the 
values corresponded to 548 µM for the standard and 65 µM for the hydroalcoholic 
extract (Fig. 1 A and B). Artemisinin contained in hydroalcoholic extract was found 
to exert cytotoxic activity with a dose one order of magnitude lower than pure 
artemisinin. 
 
Figure 1. Effect of artemisinin and A. annua hydroalcoholic extract on D-17 cells. Dose-response 
curve: D-17 cell viability upon treatment with different concentrations of (A) pure artemisinin and 
(B) A. annua hydroalcoholic extract. Representative images of D-17 cell morphology: (C) untreated 




Effect of Artemisia annua hydroalcoholic extract and artemisinin on cell cycle 
The effect of A. annua hydroalcoholic extract and artemisinin on D-17 cell cycle 
was evaluated by flow cytometry. Untreated cells presented a typical cytogram of 
a diploid cell population (Fig. 2A and D). As shown in Figure 2B, C and D, 
significant changes in D-17 cell cycle were highlighted in the presence of both pure 
artemisinin and hydroalcoholic extract. A significant decrease (p<0.0001) of cells 
in G0/G1 phase was observed after both treatments. Pure artemisinin caused a 
significant increase (p<0.01) of cells in S phase, while hydroalcoholic extract 
induced an evident significant (p<0.0001) increase of cells in G2/M phase.  
 
Figure 2. Cell cycle analysis of D-17 cells after 24 hours of treatment: (A) untreated cells; in 
presence of (B) 548 µM artemisinin and (C) hydroalcoholic extract corresponding to 65 µM 
artemisinin; (D) Cell cycle distribution. Data are reported as mean ± SD (n = 2). Significant 
differences vs untreated cells are indicated by *(p<0.05), by **(p<0.01) and ****(p<0.0001) (two-
way-ANOVA followed by the Bonferroni multiple comparisons). 
10 
 
Effect of Artemisia annua hydroalcoholic extract and artemisinin on 
intracellular iron 
Iron concentrations in D-17 cells were reported in Figure 3. Intracellular iron 
concentration in untreated D-17 cells was 45±6 ng/106 cells. Cells exposed to pure 
artemisinin and A. annua hydroalcoholic extract presented significantly lower 
concentrations of intracellular iron than the untreated cells (p<0.01) (Fig. 3A and 
B). The cells exposed to the extract had a lower concentration of iron than those 
treated with pure artemisinin; this difference was not statistically significant. 
 
Figure 3. Iron concentration in D-17 cells measured by atomic absorption spectrometer. Data are 
reported as mean ± SD. Different letters above the bars indicate significant differences (p<0.01 
ANOVA post hoc Tukey’s test). 
Discussion 
In the last 30 years, the anticancer activity of artemisinin and its derivatives has 
been investigated in vitro and in vivo systems, laying the bases for clinical trials 
both in human and veterinary medicine (Bhaw-Luximon and Jhurry, 2017; Efferth, 
2017). Osteosarcoma (OSA) is the most common primary bone tumour in people 
and in dogs and is characterized by locally aggressive and highly metastatic 
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behaviour (Fenger et al., 2014; Gardner et al., 2016).The development of new drugs 
is necessary to improve therapeutic outcome of OSA, in particular multiple 
resistance and metastatic OSA. Therefore, the first aim of this study was to 
investigate the cytotoxic effect of artemisinin by comparison with an 
hydroalcoholic extract obtained from A. annua, on canine osteosarcoma cell line 
(D-17). Our results demonstrated the cytotoxic effect of both artemisinin and 
hydroalcoholic extract in a dose-dependent manner on D-17. Efferth et al. (2011) 
reported a wide range of IC50 values of pure artemisinin for a panel of different 
human cell lines, from 57.1 µM for leukaemia cells to 1602 µM for HeLa cells. In 
2014, Jirangkul et al., reported IC50 values of pure artemisinin for two human 
osteosarcoma cell lines, MG63 and 148B, with IC50 of 167 µM and 178 µM, 
respectively. Therefore, the sensitivity of the canine D-17 to the artemisinin (IC50 = 
548 µM) appears to be intermediate if compared to human tumour cell lines. 
However, it has been reported that artemisinin by oral administration was poorly 
bioavailable in dogs and resulted in plasma concentration below 0.1 µM (Hosoya 
et al., 2014), hence far insufficient to achieve any therapeutic activity. To our 
knowledge, only dihydroartemisinin (DHA) cytotoxicity was evaluated on canine 
OSA cell lines. In particular, Hosoya et al. (2008) investigated the cytotoxic effect 
of DHA on four canine OSA cell lines, D-17, OSCA2, OSCA16, and OSCA50 and 
IC50 values were 8.7, 43.6, 16.8, and 14.8µM, respectively.  
In accordance with Efferth et al. (2011), who reported in HeLa cells that the 
cytotoxic effect of A. annua extract is much higher than that of pure artemisinin, 
our results indicated an IC50 for the plant extract one order of magnitude lower than 
pure artemisinin (65 and 548 µM, respectively). The same authors tested fourteen 
extracts of seven different A. annua plant materials with different 
phytogeographical origins. They extracted plants in dichloromethane (slightly 
polar) or methanol (polar) and evaluated the activity of the extracts on HeLa cells, 
obtaining IC50 values ranging from 54.1 to 275.5 μg/ml for dichloromethane 
extracts and from 276.3 to 1540.8 μg/ml for methanol extracts. A phytochemical 
investigation of the extracts by GLC–MS revealed the presence of artemisinin, 
arteanuine B, and scopoletin in all extracts, confirming in vitro the synergistic effect 
of the mixture of compounds that constitute the phytocomplex. Breuer and Efferth 
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in 2014 reported the successful use of Herba A. annua Luparte® as adjuvant 
therapy for veterinary sarcoma treatment. They found that this extract contained 
high amount of scopoletin, while artemisinin represented just a minor component. 
As A. annua extracts are generally administered via oral route, it seems unlikely 
that their effect in vivo is due to artemisinin only, but more probably is due to a 
synergistic effect of the whole phytocomplex.  
In the literature, heterogeneous results are reported on the action of artemisinin and 
its derivatives on the cell cycle arrest. It has been reported that this actives 
molecules (artemisinin and its derivatives) cause cell cycle arrest mainly in G1/G0 
phase, through downregulation of cyclin E, cyclin D1 and cyclin-dependent kinases 
2 and 4 in several tumour cell lines, including human breast cancer cells (Tin et al., 
2012), gallbladder cancer cell lines (Jia et al., 2016), neuroblastoma (Zhu et al., 
2014), lung carcinoma cells (A549) and non- small lung cancer cells (H1299) (Tong 
et al., 2016). In D-17 canine osteosarcoma cell line, pure artemisinin slightly but 
significantly increased the number of cells in S phase and this has been observed 
also by Beekman et al. (1997). On the other hand, hydroalcoholic extract caused a 
significant increase of D-17 cells at G2/M phase. Other authors found that 
artemisinin derived drugs induced G2/M cell cycle arrest. In particular, 
dihydroartemisinin induced G2 arrest in osteosarcoma cell line (Ji et al., 2011), 
ovarian carcinoma cell line (Jiao et al., 2007) and hepatocellular carcinoma cell line 
(Zhang et al., 2012), while artesunate induced G2 arrest in breast carcinoma cell 
lines (Chen et al., 2014), rat pituitary adenoma cell line (Mao et al., 2012) and 
kidney carcinoma cell lines (Jeong et al., 2015). Kim et al. (2015) evaluated the 
effect of an A. annua extract on human colon cancer cell line HCT116 and found 
that cell cycle arrest occurred at G1/S phase mediated by Akt/mTOR pathway. 
Afterwards, they demonstrated that A. annua extract induced apoptosis through the 
regulation of specific proteins such as Bax, Bak and cytochrome c in PDK1/Akt 
signaling pathways via PTEM/p53-independent manner (Kim et al., 2017). The 
difference in cell cycle phase arrest may be ascribed to the phytochemical 
variability of extracts, leading to alternative molecular interactions and hampering 
one pathway or another. More research is needed to unravel the complex 
mechanism underlying the effect of A. annua extract.  
13 
 
It is well known that cancer cells require higher iron intake than normal cells to deal 
with their enhanced metabolic demands, thus presenting in most cases an increased 
number of transferrin receptors (Ho et al., 2014; Torti and Torti, 2011). In the 
present study, iron concentrations determined in D-17 cell line are similar to those 
reported by other authors (Cerchiaro et al., 2013), though different analytical 
methods and measurement system hampered in many cases a direct comparison. 
Though preliminary, the data reported in the present research indicated that pure 
artemisinin and A. annua extract determined a significant reduction of intracellular 
iron in D-17 cells. It is well-known that iron has a key role in artemisinin toxicity, 
as the leading event in the artemisinin-induced cytotoxic cascade is represented by 
ROS generation via endoperoxide bridge cleavage by ferrous iron (Bhaw-Luximon 
and Jhurry, 2017; Efferth, 2017). Iron intracellular speciation and redox state are 
tightly regulated by several proteins and molecular pathways, not all of them fully 
unravelled. Zhou et al. (2016) identified as artemisinin targets 79 proteins involved 
mainly in membrane transport, protein trafficking, cell death and survival and 
nucleic acid metabolism. The authors hypothesized that among these proteins 
transferrin receptor, that is overexpressed in several tumour cells, could be alkylated 
by artemisinin leading to a selective iron depletion in cancer cells. A novel mode 
of iron-dependent cell death, ferroptosis, has been recently described pointing out 
the role of free iron pool (Dixon et al., 2012). It has been reported that iron enhances 
cytotoxicity of artemisinin derived drugs towards cancer cells, therefore a role of 
ferroptosis in cell death cannot be excluded (Efferth, 2017). 
Although preliminary, the data obtained in this research showed a more potent 
cytotoxic activity of the hydroalcoholic extract than pure artemisinin on D-17 
canine osteosarcoma cell line, indicating a possible synergistic effect of other 
bioactive molecules. However, phytochemical characterization of A. annua extract 
will be necessary to accurately quantify artemisinin in the extract and better 
understand other plant components that act synergistically for the final cytotoxic 
effect. Furthermore, it will be necessary to investigate the biochemical mechanism 
of action of A. annua extract, in particular the role of iron and ferroptosis. In 
conclusion, considering the similarities between human and canine osteosarcoma, 
progress in deepening knowledge and improving therapeutic protocols will 
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probably be relevant for both species, in a model of reciprocal translational 
medicine. 
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The research reported in this PhD thesis represents an additional step for the development 
of in vitro models to evaluate the biological activity of herbal products utilized in human 
and veterinary medicine. In particular, three important plants were considered, Boswellia 
serrata and Cucumis sativus traditionally used in Ayurvedic medicine and Artemisia 
annua in Traditional Chinese Medicine.  
In accordance with the Directive 2010/63/EU on the protection of animals used for 
scientific purposes and the principles of “3Rs”, in particular with the “Replacement”, in 
vitro models based on cell culture were used. 
Scientific evidences on the anti-inflammatory effect of B. serrata and C. sativus have 
been obtained on an inflammatory model developed using primary culture of porcine 
aortic endothelial cells (pAECs) stimulated by LPS, confirming the swine as an excellent 
animal model for translational medicine. 
Although preliminary, the results obtained on A. annua confirmed the cytotoxicity of an 
hydroalcoholic extract in a canine osteosarcoma cell line (D-17), supporting its antitumor 
properties and indicating a possible synergistic effect of the phytocomplex. Considering 
the similarities between human and canine osteosarcoma, dog has been confirmed an 
interesting spontaneous translational model.  
Reaffirming the importance of the phytochemical characterization of the extracts and the 
quantification of most important active molecules, in this study the principal boswellic 
acids responsible for biological activity of B. serrata were quantified and could be used 
as a tool for the evaluation of extract quality. On the other hand, a limitation of this study 
was the impossibility of characterizing C. sativus extract, while for the hydroalcoholic 
extract of A. annua, LC-MS/MS analysis to quantify artemisinin is currently ongoing.  
In conclusion, the in vitro models based on animal cell cultures have shown to be a 
significant preclinical tool, contributing to the application of the "Replacement" principle. 
Finally, this study confirmed the importance of evidence-based research in phytotherapy 
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